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Structural Studies of the Integrator Complex -- pre-UsnRNA 3'-end Processing Machinery 
Yixuan Wu 
 
The Integrator complex (INT) is a metazoan-specific group of proteins associated with RNA 
polymerase II (Pol II) that has important functions in the 3'-end processing of noncodng RNAs, 
including uridine-rich small nuclear RNA (UsnRNA) and enhancer RNA (eRNA). Recently, INT 
has also been reported to be involved in Pol II transcriptional regulation of protein-encoding 
genes. INT contains at least 14 subunits, but the function of each subunit is difficult to predicted, 
because most subunits lack identifiable domains and display little similarity with other proteins. 
The endonuclease activity of INT is carried out by its subunit 11 (IntS11), which belongs to the 
metallo-β-lactamase superfamily and is a paralog of CPSF-73, the endonuclease for pre-mRNA 
3'-end processing. IntS11 forms a stable complex with INT subunit 9 (IntS9) through their C-
terminal domains (CTDs). This dissertation describes the crystal structure of the IntS9-IntS11 
CTD complex at 2.1-Å resolution and summaries the structure-based biochemical and functional 
studies. The complex is composed of a continuous nine-stranded β-sheet with four strands from 
IntS9 CTD and five from IntS11 CTD. Highly conserved residues are located in the interface 
between the two CTDs. The structural observations on the complex are confirmed by yeast two-
hybrid assays and coimmunoprecipitation experiments. Functional studies demonstrate that the 
Int9-IntS11 interaction is crucial for proper INT function in snRNA 3'-end processing. 
The dissertation also presents the structural studies of a newly found mammalian mRNA 
deNADding enzyme, Nudt12. We determined the crystal structure of mouse Nudt12 in complex 
	
	
with the deNADding product AMP and three Mg2+ ions at 1.6-Å resolution. The structure 
provides exquisite insights into the molecular basis of the deNADding activity within the NAD 
pyrophosphate. Previous studies have reported that NAD-capped mRNAs in mammalian cells 
are hydrolyzed by the DXO deNADding enzyme. Together with biochemical and functional 
studies, we demonstrate that Nudt12 is a second mammalian deNADding enzyme structurally 
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This dissertation summarizes the projects I have researched over the course of my 
graduate study. The bulk of my work was studying the Integrator complex, which is involved in 
non-coding RNA 3’-end processing and RNA polymerase II transcriptional regulation. I also 




Integrator complex – Pre-UsnRNA 3’-end Processing Machinery 
	
Section 1.1: Overview of Transcription of UsnRNA  
	
    In humans, protein-coding genes only occupy a small fraction of the genome, yet it is 
thought that more than 40% of the genome can be transcribed into RNAs (Cheng et al., 2005). 
The untranslated RNAs, also known as non-coding RNAs (ncRNAs), are highly abundant in 
cells and some are functionally important. The Uridine-rich small nuclear RNAs (UsnRNAs, 
snRNAs) comprise a small group of functional ncRNAs in the nucleoplasm. Except for U6 and 
U6atac small nuclear RNAs that are transcribed by RNA polymerase I or RNA polymerase II, 
the remaining snRNAs are all transcribed by RNA polymerase II (Pol II) (Jawdekar & Henry, 
2008; Matera & Wang, 2014). UsnRNAs usually associate with proteins to form small nuclear 
ribonucleoprotein particles (snRNPs) (Matera, Terns, & Terns, 2007; Matera & Wang, 2014). 
U1, U2, U4/U6, U5 snRNAs are required for removal of introns in protein-coding mRNAs (Lee 
& Rio, 2015; Matera & Wang, 2014). U7 snRNA is required for 3’-end formation of replication-
dependent histone mRNA (Romeo & Schumperli, 2016) and U3 snRNA is required for 
processing of rRNA (Henras, Plisson-Chastang, O'Donohue, Chakraborty, & Gleizes, 2015). 
    Unlike mRNA, Pol II transcribed snRNA has a relatively simple gene structure (Figure 
1). It has a TATA-less promoter which comprises an enhancer-like DSE (distal sequence 
element) and an essential snRNA gene specific PSE (proximal sequence element) (Chen & 
Wagner, 2010). The transcripts of snRNA have no introns and are non-polyadenylated. The 3’-
end formation of pre-snRNA is mediated by snRNA-specific 3’-box to generate the mature 
snRNA (Egloff, O'Reilly, & Murphy, 2008). 
	
	2	
    To initiate snRNA transcription, transcription factors Oct1, Sp1, NF1 and Staf bind to 
sites in the DSE (Jawdekar & Henry, 2008). Oct-1 stabilizes binding of PTF (PSE-binding 
transcription factor)/SNAPc to the PSE through direct interaction (Murphy, 1997; Murphy, 
Yoon, Gerster, & Roeder, 1992). PTF helps to recruit the TBP (TATA-binding protein) and 
TAFs (TBP-associated factors) to the Pol II-transcribed snRNA genes to form the pre- 
initiation complex (Zaborowska, Taylor, Roeder, & Murphy, 2012). The pre-initiation complex 
recruits Pol II to the snRNA gene promoter. The phosphorylation of the carboxyl terminal 
Figure 1 Expression of human snRNA genes. The arrow on the gene represents the start site of transcription 
and the numbers below the line indicate the position of the elements with respect to the transcription start site. 
The snRNA transcript is represented in green with the cap in the 5'-end. The pre-snRNA is matured by co-
transcriptional capping and 3’-end trimming. The cleaved snRNA is exported into cytoplasm and assembles 
with the snRNP proteins. The functions of various snRNPs after reimport into the nucleus are noted. Modified 




domain (CTD) of Rpb1, the largest subunit of Pol II, plays important roles in snRNA expression. 
The CTD of Rpb1 comprises 52 repeats of the consensus heptapeptide Y1S2P3T4S5P6S7. With 
different phosphorylation status of the heptad repeats, CTD regulates the recruitment of different 
transcription factors and snRNA processing factors (Figure 2) (Guiro & Murphy, 2017). Soon 
after initiation of transcription, the subunit of TFIIH, CDK7 (cyclin-dependent kinase 7) 
phosphorylates Ser5 and Ser7 (Akhtar et al., 2009). Ser7P mediate recruitment of RPAP2, which 
dephosphorylates Ser5P and recruits an incomplete Integrator complex including IntS1, IntS4, 
IntS5, IntS6 and IntS7 (Egloff, Zaborowska, Laitem, Kiss, & Murphy, 2012). The catalytic 
subunit IntS11 is recruited to activate 3’-box recognition and RNA 3’-end cleavage after Ser2 is 
phosphorylated by CDK9 kinase subunit of P-TEFb (positive-transcription elongation factor b) 
(Egloff et al., 2010). After 3'-end cleavage, the snRNA is exported to the cytoplasm through the 
activity of the snRNA-specific export factor PHAX (phosphorylated adapter for RNA export) 
(Ohno, Segref, Bachi, Wilm, & Mattaj, 2000) and then undergoes the snRNP biogenesis pathway 








Section 1.2: The Integrator Complex in snRNA 3’-end Processing 
	
The Integrator complex (INT) was discovered due to its binding affinity to the CTD of 
Rpb1 (Baillat et al., 2005). There were twelve subunits identified in INT from the original 
affinity purification (Baillat et al., 2005). The twelve INT subunits were named from IntS1 to 
IntS12 based on their molecular weights, where IntS1 is the largest subunit with a molecular 
mass of 244 kDa. and IntS12 is the smallest at 48 kDa (in humans) (Figure 3)	(Baillat et al., 
2005; Baillat & Wagner, 2015). Two additional INT subunits, C12orf11 (Asunder) and C15orf44 
(also known as VWA9 or CG4785), were identified by subsequent proteomic analyses and were 
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termed IntS13 and IntS14 respectively (Figure 3)	(Chen et al., 2012).	
INT is present only in metazoans. The total molecular weight of 14 subunits is over one 
million Dalton, with eight out of fourteen subunits possessing molecular weights greater than 
100 kDa. Most INT subunits have no identifiable paralogs within the human genome and lack 
recognizable domains that would suggest a role in RNA processing. The most common predicted 
motifs within INT subunits are alpha-helical repeats such as HEAT, ARM and TPR, or VWA 
domain (Chen & Wagner, 2010), which indicate potential protein-protein interaction surfaces. 
There are two exceptions, IntS11 and IntS9, which do share homology with CPSF-73 and CPSF-
100 respectively (Baillat et al., 2005). CPSF-73 and CPSF-100 are involved in the cleavage of 
pre-mRNAs and replication-dependent histone pre-mRNAs and belong to a class of zinc-
dependent nucleases called the β-CASP (CPSF, Artemis, SMN1/PSO2) family (Callebaut, 
Moshous, Mornon, & de Villartay, 2002b; Mandel et al., 2006) (Figure 4).  
INT has been implicated in the 3'-end formation of snRNA since its first description 
(Baillat et al., 2005). In addition to its association with Pol II CTD, INT was shown to be present 
at the promoter, body and 3'-end of the snRNA by chromatin immunoprecipitation (ChIP) 
experiments (Baillat et al., 2005). Most importantly, RNAi-mediated knock-down of various INT 
subunits leads to the accumulation of misprocessed pre-UsnRNA (Baillat et al., 2005). A 
possible mechanism for snRNA 3'-end processing is that once INT is recruited to the promoter of 
snRNA and associates with Pol II CTD, the 3’-box is recognized by certain INT subunits so that 
the INT catalytic subunits can cleave the nascent pre-snRNA (Figure 5) (Guiro & Murphy, 
2017). IntS11 is the presumable catalytic subunit in INT responsible for pre-snRNA cleavage 
since their high sequence similarity to CPSF-73. Overexpression of an IntS11 catalytic mutant 
interfered with snRNA 3'-end processing (Baillat et al., 2005), indicating the importance of its 
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endonuclease activity in snRNA 3'-end processing. ChIP analysis of U2 snRNA shows that 
IntS11 is mainly associated with the 3’-box, whereas IntS5 is found associated with both the 
snRNA gene promoter region and the 3'-box (Egloff et al., 2012). Therefore, the INT complex 
may assemble in a stepwise manner, with some subunits playing a role early in transcription 
initiation and elongation, while others are later recruited for snRNA 3'-end processing.  
Besides the function in UsnRNA 3'-end cleavage, INT was also shown to play a role in 
UsnRNA gene transcription termination. Knockdown of IntS11 or IntS9 results in an increased 
level of Pol II occupancy downstream of the 3'-end cleavage site, demonstrating that snRNA 3'-
end processing is linked to transcription termination (O'Reilly et al., 2014). However, the 





Figure 3 Integrator subunit domain schematic. Predicted protein domains of 14 Integrator subunits are 
illustrated. The length indicated are from human orthologues (in amino acids, aa). Modified from (Baillat 





Figure 4. Comparison of transcription and processing of (a) snRNA and (b) mRNA. The INT is required 
for recognition of snRNA downstream processing signals, including 3’-box. Two of its subunits, IntS11 
and IntS9, share sequence similarity to the mRNA 3’-end processing factors CPSF-73 and CPSF-100. For 
both snRNAs and mRNAs, 5’-end capping and 3’-end cleavage are thought to occur co-transcriptionally. 




Figure 5 Model of INT function in UsnRNA processing (Guiro & Murphy, 2017). INT is recruited early 
in the UsnRNA transcription cycle and associates with Pol II CTD through recognition of the ser7P/ser2P 
dyad. Upon transcription, the UsnRNA terminal stem loop and 3'-box are recognized by unknown factors. 
The heterodimeric cleavage factor IntS9/IntS11 then carries out UsnRNA cleavage.  
 
Section 1.3 Role of Integrator Complex in Pol II Transcriptional Pause-Release 
	
In addition to its function in UsnRNA biosynthesis, INT has been recently shown to play 
a critical role in the activation of protein-coding genes, especially in the Pol II pause-release and 
elongation (Gardini et al., 2014; Skaar et al., 2015; Stadelmayer et al., 2014). Pol II pausing is an 
important step in controlling gene expression and regulating biological processes. It occurs late 
during the initiation stage of transcription, beginning with the recruitment of Pol II and basal 
transcription factors to the promoter to form the pre-initiation complex (PIC) (Luse, 2013). Pol II 
escapes the promoter after transcribing 9-10 nt nascent RNA, and serine 5 residues of Rpb1 CTD 
heptad repeats are phosphorylated. Pol II may pause when the transcript is 20-50 nt long, and the 
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productive elongation is activated only after pause release (Zhou, Li, & Price, 2012). Pol II 
pausing occurs prevalently both at highly transcribed genes and at those genes that are 
transcribed at very low levels and are poised for activation (e.g. heat shock genes) (Gaertner & 
Zeitlinger, 2014). The paused PoI II is stabilized by promoter-associated transcription factors 
(TFs) together with negative elongation factor (NELF) and DRB-sensitivity-inducing factor 
(DSIF) (Yamaguchi, Shibata, & Handa, 2013). Release of paused Pol II requires the kinase 
activity of the P-TEFb complex, which is composed of the cyclin T1 and cyclin-dependent 
kinase 9 (CDK9) (Yamaguchi et al., 2013; Zhou et al., 2012). Once P-TEFb is recruited to the 
promoter by specific TFs and cofactors, it phosphorylates the repressive DSIF/NELF complex, 
causing NELF to dissociate from Pol II and transforming DSIF into a positive elongation factor 
(Yamaguchi et al., 2013; Zhou et al., 2012). P-TEFb also phosphorylates the CTD of Pol II at 
Ser2 to create a platform for binding RNA processing and chromatin modifying factors that 
facilitate productive RNA synthesis (Peterlin & Price, 2006). The detailed mechanism of P-TEFb 
recruitment to transcriptionally active genes is not clear. Recent biochemical studies 
demonstrated a large multi-subunit complex termed Super Elongation Complex (SEC) which 
contains an active P-TEFb as well as other elongation factors (Lin et al., 2010; Luo, Lin, & 
Shilatifard, 2012). The discovery of SEC suggests the involvement of additional factors in Pol II 
pause-release.   
Surprisingly, INT has been recently found to play an important role in the regulation of 
transcription initiation as well as Pol II pause-release at immediate early genes (IEGs) following 
transcriptional activation by epidermal growth factor (EGF) in human cells (Gardini et al., 2014). 
IEGs are known to be regulated through Pol II pause-release. Under starvation conditions, low 
levels of INT were detected using antibodies against IntS1, IntS11, and IntS9 at IEG 
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transcription start sites (TSSs); however, after EGF stimulation, INT occupancy markedly 
increased at the TSS and within the body of the gene. Depletion of IntS1 and IntS11 through 
short hairpin RNA (shRNA) abrogated responsiveness of IEGs to EGF stimulation. Moreover, 
knockdown of Integrator subunits caused failure of Pol II to escape pausing and progress into 
productive elongation. Further ChIP-seq analysis showed that depletion of INT also abolished 
the stimulus-dependent recruitment of two SEC components, ELL2 and AFF4, to IEGs. 
Collectively, this study indicates that INT is also recruited to protein-coding genes and plays a 
critical role in transcription initiation and Pol II pause-release by association with the SEC 
complex (Figure 6) (Baillat & Wagner, 2015). 
Another study revealed the function of INT in regulating Pol II pause-release by 
interacting with NELF (Stadelmayer et al., 2014). Both biochemical and functional assays 
showed that INT subunits specifically controlled NELF-mediated Pol II pause-release at coding 
genes. Surprisingly, IntS3 and IntS11 had the opposite effect on NELF-mediated Pol II pausing. 
Genes containing NELF and IntS3 correlates with low Pol II density at the TSS and increased 
Pol II in gene bodies. In complete agreement, IntS3 knockdown reduces Pol II occupancy over 
gene bodies. By contrast, IntS11 depletion increases Pol II occupancy and RNA-seq read density 
over gene bodies but not over termination sites, resulting in defects in Pol II processivity and 
RNA processing. In this study, INT-mediated regulation of coding genes is restricted to NELF-
target genes. Moreover, the data suggest that the catalytic activity of IntS11 may play a role in 
regulating Pol II pause-release and Pol II processivity. Interestingly, in INT target coding genes, 
a 3’-box sequence was found close to the termination sites. The presence of the 3’-box was 
associated with a decrease in RNA levels over termination sites in IntS11-depleted cells and 
suggested a functional contribution of the 3’-box in IntS11-mediated regulation of RNA 
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processing. Therefore, INT may play an important role in coupling the Pol II pause-release to 
mRNA processing. 
         
Figure 6 INT role in Pol II pause-release (Baillat & Wagner, 2015). Top, under starvation conditions, Pol 
II starts the transcription and pauses 40-60 nt downstream of the TTS. INT together with the NELF and 
DSIF is associated with Pol II CTD through phosphorylation state recognition. Middle, upon stimulation, 
INT is further enriched at the pause site and recruits P-TEFb and SEC. Bottom, P-TEFb phosphorylates 
the Pol II CTD Ser2, DSIF and NELF. NELF dissociates from the complex, and DSIF becomes a positive 




Section 1.4 Integrator mediates enhancer RNA (eRNA) biogenesis 
	
Recently, INT was shown to mediate the biogenesis of enhancer RNA (eRNA) as well 
(Lai, Gardini, Zhang, & Shiekhattar, 2015). Enhancers are distal regulatory elements which are 
involved in tissue- and temporal-specific regulation of gene expression in metazoans. Enhancers 
regulate transcription of particular genes allowing cell-type and cell-state specificities of gene 
expression (Pennacchio, Bickmore, Dean, Nobrega, & Bejerano, 2013). Enhancer RNAs 
(eRNAs) are transcripts derived from enhancers and are suggested to play a role in 
transcriptional regulation both in cis and in trans (Pennacchio et al., 2013). 
Lai et al. revealed that INT was recruited to enhancers and super-enhancers in a signal-
dependent manner using starving HeLa cells (Lai et al., 2015). After starving for 48 h, HeLa 
cells were stimulated with EGF to induce IEGs. INT occupancy over enhancers were measured 
using antibodies against IntS1, IntS9 and IntS11 before and after EGF stimulation. Before EGF 
induction, enhancers were occupied by a detectable amount of INT. After addition of EGF, INT 
was further recruited to enhancers. Depletion of IntS11 and IntS1 using shRNAs reduced the 
production of eRNA after EGF stimulation and a significant decrement in level of EGF-
responsive protein-coding gene transcripts in proximity of these EGF-induced enhancers was 
also observed. Stimulus-induced enhancer-promoter chromatin looping were also abrogated upon 
INT depletion, thus inhibiting enhancer and promoter communication. After INT depletion, 
eRNAs were found to remain bound to Pol II and their primary transcripts accumulated. This 
observation suggests a block in 3'-end cleavage of primary eRNA transcripts and a defect in 
termination. Indeed, IntS11 catalytic activity was demonstrated to be required to regulate eRNA 
induction since the catalytic mutant of IntS11 failed to rescue the EGF-induced eRNA levels 
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following endogenous IntS11 depletion. These results confirmed the important role of INT 
cleavage activity in eRNA transcription termination. 
Interestingly, eRNA has been reported to facilitate the transition of paused Pol II into 
productive elongation by acting as a decoy for NELF complex upon induction of IEGs 
(Schaukowitch et al., 2014). This model could link the diverse functions of INT during 
transcription. When at promoter, INT regulates pause-release factors, leading to modulation of 
productive transcriptional elongation. When at enhancers, INT governs eRNA maturation and 
enhancer-promoter communications. 
 
Section 1.5 The Pathophysiology of Integrator 
 
As mentioned above, INT is a multifunctional complex that regulates Pol II-mediated 
transcription at different gene classes. The improper function of INT is expected to alter diverse 
cellular pathways and biological processes. Indeed, several INT subunits have been found to play 
important roles in DNA damage response, adipose tissue differentiation, embryonic 
development, ciliogenesis, lung homeostasis, the Cajal body (CB), and herpesvirus microRNA 
3'-end formation (Hata & Nakayama, 2007; Jodoin et al., 2013; Kapp, Abrams, Marlow, & 
Mullins, 2013; Kheirallah, de Moor, Faiz, Sayers, & Hall, 2017; Otani et al., 2013; Takata, 
Nishijima, Maeshima, & Shibahara, 2012; Tao, Cai, & Sampath, 2009; Zhang, Ma, & Yu, 2013). 
Dysfunction of INT may also lead to various pathologies in humans. Genetic and molecular 
studies have detected the presence of mutations or altered expression levels in genes coding for 
INT subunits in several diseases, including malignancies (Rienzo & Casamassimi, 2016). Table 




Table 1 Human INT subunits and their possible pathophysiological roles (Rienzo & Casamassimi, 2016). 
Name Recognizable domains Pathophysiological role 
IntS1 DUF3677 Development at early blastocyst stage 
Hematopoietic development 
IntS2 — Gastric cancer peritoneal carcinomatosis 
IntS3 DUF2356 DNA damage response and maintenance of genome 
stability 
Overexpressed in hepatocellular carcinoma 
IntS4 ARM, HEAT Development 
IntS5 — Hematopoietic development 
Postmenopausal osteoporosis 
IntS6 VWA, ISDCC Adipogenesis, Overgrowth, DNA damage response 
Pathogenesis of hepatocellular carcinoma (with its 
pseudogene INTS6P1) 
Childhood B-precursor acute lymphoblastic leukemia 
IntS7 ARM DNA damage response 
Development 
IntS8 TRP Putative biomarker for gastric cancer 
Mutated in peripheral T cell lymphoma 
IntS9 metallo-β-lactamase, β-CASP Possible role in malignancies 
IntS10 — Nicotine dependence (GWAS) 
Childhood B-precursor acute lymphoblastic leukemia 
IntS11 metallo-β-lactamase, β-CASP Adipogenesis 
Hematopoietic development 
Possible role in malignancies 
IntS12 PHD Lung function and pulmonary diseases 
IntS13 COIL Spermatogenesis and oogenesis 
Cell division 
IntS14 VWA Elevated expression in SV40-immortalized cells, cancer 
cells, and NSCLC tissues 
 
 
Section 1.6 Integrator Cleavage Module 
 
Although INT was originally purified as a single entity, ChIP experiments indicate that 
INT appears to act as a modular complex on the genome. Different INT subunits give distinct 
occupancy patterns on UsnRNA genes in human or on the HSP70 gene in fly. On human U2 
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snRNA, IntS5 shows predominant occupancy from the promoter to the 3’-box, whereas IntS11 is 
mainly associated with the 3’-box (Egloff et al., 2012). For Drosophila HSP70 gene, IntS12 is 
present at the promoter and peaks at the transcriptional pausing site while IntS9 is shifted toward 
the 3’-end of the gene with a marked peak in the gene body (Gardini et al., 2014). These 
observations would indicate a modular complex of INT that assembles in a stepwise manner with 
different functions during the transcription cycle. A module containing IntS5 or IntS12 could be 
recruited early with a role in transcription initiation and pausing, while IntS9 and IntS11 are 
recruited later to form a module that functions in elongation and 3’-end processing.  
While much progress has been made since the discovery of INT, many issues still remain 
unsolved. Little is known about the putative existence of modules and sub-complexes within the 
complex. Also, the interactions between the identified subunits, as well as between INT subunits 
and other protein factors involved in transcription regulation need to be further investigated. 
Moreover, it is very difficult to predict the function and the mechanism of the majority of INT 
subunits, because most subunits share little sequence homology with other proteins and have few 
recognizable domains, and the structural information on these subunits is very limited.  
As mentioned in Section 1.2, IntS11 and IntS9 are paralogues of the cleavage and 
polyadenylation specificity factors CPSF-73 and CPSF-100. CPSF-73 carries out the 
endonuleolytic cleavage for the processing of either pre-mRNA or replication-dependent histone 
pre-mRNA (Dominski, Yang, & Marzluff, 2005; Mandel et al., 2006). It is known that CPSF-73 
and CPSF-100 together with a scaffold protein called Symplekin form a complex named Core 
Cleavage Complex (CCC) (Michalski & Steiniger, 2015; Sullivan, Steiniger, & Marzluff, 2009) 
or mCF (mammalian cleavage factor) (Shi & Manley, 2015). These three proteins then interact 
with other factors in the processing machinery to catalyze cleavage of the pre-mRNA. Depletion 
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of Symplekin from Drosophila S2 cells leads to extreme misprocessing of histone pre-mRNA, 
which is similar to depletion of CPSF-73 and CPSF-100 (Sullivan et al., 2009; Wagner et al., 
2007).  
In the context of INT, no candidate 'Symplekin-like' subunit could be readily identified, 
because there are no other INT subunits sharing homology with members of the cleavage and 
polyadenylation machinery except for IntS9 and IntS11. A recent study using modified yeast 
two-hybrid screen determined that IntS4 binds to IntS9-IntS11 heterodimer, indicating a possible 
'Symplekin-like' role of IntS4 (T. R. Albrecht et al., 2018). Although there is no significant 
homology detected between Symplekin and IntS4, there are some similarities in the two proteins. 
IntS4 has a similar size to Symplekin. Both proteins possess HEAT repeats. The structure 
prediction of IntS4 identified an array of N-terminal HEAT repeats over the first 800 amino 
acids. The remaining 200 amino acids at the C-terminal end are predicted to be rich in β-strands. 
IntS4 was found to bind to IntS9 and IntS11 only when they form the IntS9-IntS11 heterodimer 
through their CTDs.  Similar to depletion of IntS11 or IntS9, depletion of IntS4 also leads to 
severe UsnRNA misprocssing. Consistently, siRNA knockdown of these subunits in HeLa cells 
causes complete disassembly of Cajal bodies and histone locus bodies (T. R. Albrecht et al., 
2018; Takata et al., 2012). Cajal bodies and histone locus bodies are two major nuclear bodies 
that are primarily nucleated around snRNA and clustered replication-dependent histone genes 
and are involved in snRNA biogenesis and histone mRNA production (T. R. Albrecht et al., 
2018). Altogether, these data propose a model that IntS4, IntS9, and IntS11 constitute a minimal 
Integrator cleavage module. 
 




Since its discovery, INT has been added to the Pol II-mediated transcription machinery as 
one of the major components. INT plays roles in transcriptional initiation, stimulus-dependent 
Pol II pause-release, and termination of various gene classes. The multiple functions could be 
explained by the existence of different INT sub-complexes or modules, which could be 
sequentially recruited during different transcriptional stages; alternatively, subunits within INT 
could adopt major conformational changes when involved in different processes of the 
transcription cycle. However, future evidences are needed to prove these hypotheses. 
Here, we performed structural studies of several INT subunits that are indicated to be 
essential for INT functions in various processes. Chapter 2 presents the crystal structure of 
human IntS9-IntS11 CTD complex, which uncovers an extensive molecular interface that could 
allow recognition by other subunits of INT. Based on structural observations, biochemical and 
functional studies were conducted, demonstrating the IntS9-IntS11 CTD interaction is functional 
important.  
In Chapter 3, I will present my work on structure determination of Nudt12, a novel 
mammalian deNADding enzyme. The redox cofactor nicotinamide adenine dinucleotide (NAD) 
was recently reported to be covalently linked to the 5'-end of eukaryotic mRNAs (Jiao et al., 
2017). The mammalian non-canonical decapping enzyme, DXO, possesses deNADding activity 
by removing the entire NAD moiety from the 5'-end of NAD-capped RNA in cells (Jiao et al., 
2017). Our crystal structure of mouse Nudt12 in complex with the deNADding product AMP 
and three Mg2+ interprets the molecular basis of Nudt12 deNADding activity. The structural 
observations as well as results from biochemical and functional studies demonstrate that Nudt12 





Structural and Functional Studies of Human IntS9-IntS11 CTD 
Complex 
 
Section 2.1: Introduction 
 
The Integrator complex (INT) is characterized as the machinery responsible for 3'-end 
processing of noncoding RNAs, including the uridine rich small nuclear RNA (UsnRNA) and 
enhancer RNA (eRNA), but its molecular mechanism of action is poorly understood. So far, a 
large amount of efforts has been made to understand the 3'-end processing of the other two 
classes of Pol II transcripts, poly(A)+ mRNA and the replication-dependent histone mRNA. 
Although the cis elements of these two kinds of RNAs are quite different and their respective 3'-
end formation complexes comprise different protein factors, both poly(A)+ pre-mRNA and 
histone pre-mRNA are cleaved by a cleavage core consist of CPSF-73, CPSF-100 and 
Symplekin (Jurado, Tan, Jiao, Kiledjian, & Tong, 2014; Millevoi & Vagner, 2010; Romeo & 
Schumperli, 2016).  
CPSF-73 is an RNA endonuclease and belongs to the metallo-β-lactamase superfamily 
(Mandel et al., 2006). The general architecture of metallo-β-lactamase proteins consists of an 
αβ/βα sandwich with two zinc ion binding sites located at the top of the β sandwich. The residues 
that coordinate Zn2+ ions are conserved among active metallo-β-lactamase proteins (Aravind, 
1999). The active site of metallo-β-lactamase family proteins are formed by 5 signature motifs 
(motif 1 to 5) (Aravind, 1999). A unique feature for CPSF-73 and other nucleic acid 
endonucleases within metallo-β-lactamase family is that motif 5 is replaced with three additional 
motifs (motif A to C) and a motif called the β-CASP (CPSF, Artemis, SNM1/PSO2) is inserted 
within the metallo-β-lactamase domain (Callebaut, Moshous, Mornon, & de Villartay, 2002a). 
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The crystal structure of CPSF-73 catalytic segments including the metallo-β-lactamase domain 
and β-CASP motif demonstrated its endonuclease activity (Mandel et al., 2006). The inserted β-
CASP motif forms a separate domain that is located above the metallo-β-lactamase domain, 
where both N- and C- terminal regions of the protein are involved in forming the metallo-β-
lactamase domain (Figure 7) (Mandel et al., 2006). As shown in the structure, the active site is 
positioned in the interface between β-CASP motif and the metallo-β-lactamase domain which 
seems to be inaccessible to its substrates. Indeed, in vitro assay using standard conditions for 3’-
end processing reactions showed weak endonuclease activity of CPSF-73, which was consistent 
with the observations from the structure (Mandel et al., 2006). This has led to the hypothesis that 
β-CASP endonuclease may require conformational changes to activate catalysis. 
Figure 7  Structures of human CPSF-73 and yeast CPSF-100 (Ydh1p). a, Schematic representation of the 
structure of human CPSF-73. The β-strands and α-helices are labeled, and the two zinc atoms in the active 
site are shown as gray spheres. The sulfate ion is shown as a stick model.  b, Schematic representation of 
the structure of yeast CPSF-100. The zinc atoms in the CPSF-73 structure are shown for reference. From 




CPSF-100 is another cleavage and polyadenylation specificity factor in the pre-mRNA 3'-
end cleavage core. CPSF-100 is thought to interact with CPSF-73 to form a heterodimer that is 
recruited to pre-mRNA substrates to elicit processing (Dominski, Yang, Purdy, Wagner, & 
Marzluff, 2005). CPSF-100 also belongs to the β-CASP family. However, CPSF-100 contains 
residue substitutions at the active site so that it seems to have no endonuclease activity. The 
overall structure of yeast CPSF-100 is similar to that of human CPSF-73 (Mandel et al., 2006). 
The function of the inactive CPSF-100 is unknown. One hypothesis is that it helps activate 
CPSF-73 by inducing conformational changes through heterodimerization. 
As mentioned in Chapter 1, IntS11 and IntS9 are paralogs of CPSF-73 and CPSF-100 in 
INT. IntS11 and IntS9 are both members of β-CASP family (Baillat et al., 2005). IntS11 shares 
high homology with CPSF-73 within the N-terminal metallo-β-lactamase domain and the β-
CASP domain (40% identity). The sequence conservation between IntS9 and CPSF-100 is 
weaker, and IntS9 has two insertions in the metallo-β-lactamase domain (Wu, Albrecht, Baillat, 
Wagner, & Tong, 2017). Similar to CPSF-100, IntS9 also has residue changes in the active site 
and is predicted to be inactive. The existence of inactive form of cleavage factor in both 
machineries indicates their functional importance for 3'-end cleavage. 
Beside the metallo-β-lactamase and β-CASP domains, IntS9, IntS11, CPSF-73, and 
CPSF-100 all contain a C-terminal domain (CTD) (Figure 8).  The sequence conservation of 
CTDs is much poorer. Previous studies showed that the CTDs of IntS9 and IntS11 are required 
and sufficient to mediate their heterodimerization (T. R. Albrecht & Wagner, 2012). The 
interaction between IntS9 and IntS11 is critical for snRNA 3'-end processing (T. R. Albrecht & 
Wagner, 2012). In order to understand the molecular basis of this association, we have 
determined the crystal structure of the IntS9-IntS11 CTD complex (Wu et al., 2017). 
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Additionally, we designed mutations based on the structure that disrupt the IntS9-IntS11 
interaction. We demonstrated that disruption of IntS9-IntS11 interaction also abolishes U7 
snRNA 3'-end processing. 
 
 
Figure 8 Domain organizations of (A) IntS11, CPSF-73, (B) IntS9 and CPSF-100. The metallo-β-
lactamase domain is in cyan. The β-CASP motif is in yellow. Red lines indicate the conserved residues in 
the active site. From (Wu et al., 2017). 
 
 
Section 2.2 Experimental Procedures 
     
Protein Expression and Purification 
The C-terminal domain of human IntS11 (residues 491–600) was subcloned into the 
pET28a vector (Novagen), which introduced an N-terminal His-tag. The C-terminal domain of 
human IntS9 (residues 582–658) was subcloned into the pCDFDuet vector (Novagen) without 
any affinity tag. The two proteins were coexpressed in Escherichia coli BL21Star (DE3) cells at 
23 °C for 16–20 h. The cells were lysed by sonication in a buffer containing 20 mM Tris (pH 
8.5), 200 mM NaCl, and 5% (vol/vol) glycerol. The IntS9–IntS11 heterodimer was purified by 
Ni-NTA (Qiagen) chromatography. The eluted protein was treated overnight with thrombin at 
4 °C to remove the His-tag and was further purified by gel filtration chromatography (Sephacryl 
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S-300; GE Healthcare). The purified protein was concentrated to 30 mg/mL in a solution 
containing 20 mM Tris (pH 8.5), 200 mM NaCl, and 10 mM DTT before being flash-frozen in 
liquid nitrogen and stored at −80 °C. 
    
Protein Crystallization 
Crystals of the IntS9–IntS11 CTD complex were obtained at 20 °C using the sitting-drop 
vapor-diffusion method. The reservoir solution contained 0.1 M Bis-Tris (pH 6.5) and 21–24% 
(wt/vol) PEG 3350. The protein concentration was 10 mg/mL. Crystals took 2 wk to grow to full 
size. A heavy-atom derivative was prepared by soaking native crystals in the mother liquor with 
1 mM HgCl for 3 h. All crystals were cryo-protected by the reservoir solution supplemented with 
5% (vol/vol) ethylene glycol and were flash-frozen in liquid nitrogen for data collection at 100 
K. 
 
Data Collection and Processing 
X-ray diffraction data of native and heavy-atom–derivative crystals were collected at a 
wavelength of 0.979 Å on an ADSC Q315R CCD at the 5.0.1 beamline of Advanced Light 
Source (ALS). The diffraction images were processed with the HKL program (Otwinowski & 
Minor, 1997). The crystals belonged to space group P21 with cell dimensions of a = 63.0 Å, b = 
67.8 Å, c = 98.6 Å, and β = 100.6°. There are four copies of the IntS9–IntS11 complex in the 
crystallographic asymmetric unit. A native dataset was collected to 2.1-Å resolution, and the 
derivative dataset was collected to 2.3-Å resolution. 
 
Structure Determination and Refinement 
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Four Hg atoms were located and used for phasing by the AutoSol routine in PHENIX 
(Adams et al., 2002b), using the single isomorphous replacement (SIR) method. Most of the 
protein residues were automatically built by the AutoBuild routine in PHENIX, and further 
manual building was carried out with the program Coot (Emsley & Cowtan, 2004b). The 
structure was refined using PHENIX. The crystallographic information is summarized in Table 
2. 



































Section 2.3.1 Constructs Design and Soluble Protein Expression 
	
Previous studies have shown the binding site within IntS11 for IntS9 is approximately 
from residue 418-597 (Drosophila), and the interacting region within IntS9 is between residue 
565 and 658 (T. R. Albrecht & Wagner, 2012). The initial constructs for protein expression were 
made using Drosophila genes. For Drosophila IntS11 (dIntS11) CTD, constructs were designed 
with constant C-terminus while varying the N-terminus (Figure 9). For Drosophila IntS9 
(dIntS9), constructs were designed with variant N- and C-termini (Figure 9). To obtain IntS9-
IntS11 CTD complex, Int9 and IntS11 CTD genes were subcloned into pET28a/pET26b (with 
His-tag) or pCDFDuet (without His-tag). Different combination of dIntS11 and dIntS9 CTD 
constructs were achieved by co-transforming pET and pCDFDuet vectors into E. coli expression 
system.  
 
Figure 9 Constructs for dIntS11 and dIntS9 CTD. The domain organization, secondary structure 
prediction, and conservation information of IntS11 and IntS9 are shown in bars with bold border. The top 
	
	26	
row indicates domain organization, where metallo-β-lactamase domain (MBL) is in cyan and β-CASP 
motif (BCASP) is in yellow. The middle row shows the secondary structure prediction. α-helix is 
represented in yellow and β-strand is in cyan. The bottom row shows the sequence conservation (IntS11: 
6 orthologs; IntS9: 7 orthologs). The blue means the least conserved and the black means absolutely 
conserved. The constructs of each Drosophila protein are shown as six short bars. 
 
After some expression trials, we found that dIntS9 CTD required His-tag to achieve 
optimal yield.  The minimal region within dIntS11 for binding dIntS9 CTD is residue 471-597, 
and the smallest dIntS9 CTD construct that could pull down dIntS11 CTD contains residue 560 
to 654 (Figure 10).  
The constructs for human IntS11 (hIntS11) and human IntS9 (hIntS9) were designed 
based on the information from Drosophila protein expression. Residue 491-600 of hIntS11 and 
residue 582-658 of hIntS9 were two smallest constructs that we found to form heterodimer 





Figure 10 Sequence alignment of IntS11 CTD and IntS9 CTD. The predicted secondary structure 
elements in Drosophila IntS11 and IntS9 are shown in black in above the sequences, and the predicted 
secondary structure elements in human IntS11 and IntS9 are shown in blue and pink respectively below 
the sequences. The vertical arrows above or below the sequences indicate the minimal constructs for CTD 
interaction. Dm, Drosophila melanogaster; Hs, Homo sapiens; Mm, Mus musculus; Rn, Rattus 
norvegicus; Dr, Danio rerio; Xt, Xenopus tropicalis; Xl, Xenopus laevlis. Modified from an output from 






Figure 11 Size exclusion chromatography of human IntS9-IntS11 CTD complex.  The eluted fractions 
were monitored for protein content using A280. The peak fractions were analyzed by SDS-PAGE and 
visualized by Coomassie blue staining (gel inset). 
 
 
The human IntS9-IntS11 CTD complex was purified using Ni-NTA followed by 
Sephacryl S-300 gel filtration chromatography (Figure 11). Based on SDS-PAGE, the bottom 
two bands represent His-IntS11-CTD (13.6kDa) and IntS9-CTD (8.9kDa) respectively (Figure 
11). There was a third band at around 27kDa enriched in protein eluate from Ni-NTA which we 
initially thought to be an impurity protein. But this band coeluted with the CTD complex and got 
much fainter during gel filtration. Later we confirmed this band to be the IntS11 CTD dimer 
band and was formed through an intermolecular disulfide bond. In the elution buffer, where no 
DTT existed, IntS11 CTD formed dimers through disulfide bonds. In gel filtration buffer, there 
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was 10mM DTT. The disulfide bonds were reduced so that the dimer band disappeared. 
Although the SDS-PAGE sample buffer contains the reducing agent β-mercaptoethanol (β-ME) 
which should have reduced the disulfide bond, the sample buffer I used was made years ago and 
the β-ME had decomposed.  
 
Section 2.3.2 Crystal Screening and Optimization 
 
The purified human IntS9-IntS11 CTD complex was screened for crystallization 
conditions with several commercial crystallization kits (Cudney, Patel, Weisgraber, & 
Newhouse, 1994; Jancarik, Scott, Milligan, Koshland, & Kim, 1991) by sitting drop vapor 
diffusion at 20 ℃. Rectangular plate shaped crystals appeared in a condition containing 0.1M 
Tris (pH 7.0), 20% (w/v) PEG 1000 (Figure 12a). The crystal diffracted to 2.6-Å resolution with 
a space group P21.  But the crystal was unable to be reproduced, so we could not solve the 
structure because of phase problem.	 
 
 
Figure 12 Initial crystals for human IntS9-IntS11 CTD complex. (a) Rectangular plate shaped crystals in 
the drop. (b) Lane P, purified protein solution sample for crystallization; Lane C, crystal sample, crystals 





In order to figure out why the protein could not crystallize, initial crystals were analyzed 
by SDS-PAGE (Figure 12b). By comparing the crystal sample with the original protein sample, 
we found that the IntS11 CTD dimer band shifted downward by 2~3kDa. We suspected that the 
protein might be digested by a contaminating protease in the contaminate during crystallization, 
and the degradation products were easier to crystallize. Based on this information, we performed 






Figure 13 Limited proteolysis of human IntS9-IntS11 CTD complex. IntS9-IntS11 CTD complex protein 





from each reaction were taken at different time and were boiled and frozen in -20 ℃ before loading on 




The limited proteolysis results showed that IntS9 CTD (residue 582-658) bands were 
very stable in all three reactions (Figure 13). The N-His-IntS11 CTD (residue 491-600) construct 
was eventually digested into a smaller protein with the size similar to what we observed in 
crystal samples. The digestion products for three different proteases shifted to around the same 
position on SDS-PAGE, which indicated a compact region of the protein. Before we design any 
new truncations, we thought what was removed from the original construct by protease might be 
the flexible N-His tag. Proteins without His-tag were then purified and used for crystallization 
(Figure 14). Fortunately, crystals were observed in several conditions this time (Figure 15). 
 
 







Figure 15 Crystals of thrombin treated human IntS9-IntS11 CTD complex from screening. 
 
 
The common contents from these conditions are Bis-Tris pH 5.5-6.5 and PEG 3350. Grid 
screen was set up to reproduce and optimize the crystals. Single crystals appeared within one 
week and grew into full-size within two weeks. Most crystals were hollow (Figure 16). The 












Section 2.3.3 Structure Determination 
 
Selenomethionine Substituted Proteins  
In order to determine the phase to solve the structure, we tried to express and purify 
selenomethionine substituted proteins for single or multiple wavelength anomalous diffraction 
(SAD or MAD) (Hendrickson, Horton, & Lemaster, 1990). The crystallizable constructs were 
transformed into methionine auxotroph B834 (DE3) cells (Novagen) and grown in LeMaster 
media supplemented with selenomethionine (Hendrickson et al., 1990). However, the yield of 
selenomethioninyl IntS9 CTD dropped dramatically. After purification, there was excess IntS11 
CTD in the protein solution. After crystallization screening, we did not get any hits from this 
sample. 
     
Heavy Atom Soaking 
Since we were unable to get selenomethionine crystals, we tried to determine the 
structure by heavy atom soaking. Native crystals were soaked in the mother liquor with four 
heavy atom compounds for 3 hours or overnight (Table 3). Three of them did not disrupt the 
diffraction quality of the crystals and seven data sets were collected with these crystals.  
After processing the data sets, the Hg-derivative dataset showed large differences to the 
native dataset by high derivative R factor and four Hg atoms were located and used for phasing 







Table 3 Summary of heavy atom derivatives 
Soak  Soaking Time Resolution (Å) 
Native None 2.1 
1mM K2PtCl4 3 hours No diffraction 
1mM KAu(CN)2 3 hours/overnight 2.5/2.7 
1mM HgCl2 3 hours/overnight 2.3/2.2 
1mM Trimethyl Pb(IV) Acetate 3 hours/overnight 2/2.1 
 
Section 2.3.4 Structure of the IntS9 and IntS11 CTDs 
 
The structure of IntS9-IntS11 CTD complex has been determined at 2.1-Å resolution 
(Figure 17). The refined atomic model has good agreement with the X-ray diffraction data and 
the expected geometric parameters. 98.1% of the residues are in the favored region of the 
Ramachandran plot, and no residues are in the disallowed region. 
The structure of IntS9 CTD (residues 582-658) contains a four-stranded, antiparallel β-
sheet (β2-β5). One face of the β-sheet is covered by two helices (α1-α2). A two-stranded 
antiparallel β-sheet (β1, β6) formed by residues near the beginning and end of the domain likely 
provides further stability to this domain. 
The structure of IntS11 CTD (residues 493-596) contains a five-stranded, antiparallel β-
sheet (β1-β5). Two helices cover one of its faces (α2-α3). A short helix (α1) precedes the first β-







Figure 17 Crystal structure of the human IntS9-IntS11 CTD complex. (a) Structure of the human IntS9-
IntS11 CTD complex. The IntS9 CTD is in pink, and the IntS11 CTD in green. (b) Structure of the 
human IntS9-IntS11 CTD complex, viewed after 90° rotation around the horizontal axis. (c) Overlay of 
the structure of IntS9 CTD (pink) with that of IntS11 CTD (green). The structure figures were produced 
with PyMOL (www.pymol.org). From (Wu et al., 2017) 
 
The last four strands (β2-β5) of the IntS11 CTD has a similar fold to that for the β-sheet 
in IntS9 CTD. The two CTD structures can be superposed with an rmsd of 2.4-Å for 64 
equivalent Cα atoms, although the sequence identity between the two proteins in this region is 
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only 16%. The two helices covering the β-sheet are located at similar positions in the two 
structures as well. A unique feature of IntS11 CTD is strand β1. It is the longest strand in the 
structure and is located in the center of the interface with IntS9. 
        Close structural homologs for IntS9 CTD include the CTD of an atypical Sm-like archaeal 
protein (Mura, Phillips, Kozhukhovsky, & Eisenberg, 2003) and the platform subdomain of the 
AP-2 complex β subunit (Schmid et al., 2006), based on a DaliLite search (Figure 18) (Holm, 
Kaariainen, Rosenstrom, & Schenkel, 2008). Close structural homologs for IntS11 CTD include 
the kinase associated-1domain (KA domain) at the C terminus of yeast septin-associated kinases 
and human MARK/PAR1 kinases (Moravcevic et al., 2010), the C-terminal domain of the 
catalytic subunit of AMP-activated protein kinase (AMPK, SNF1 in yeast) that mediates 
heterotrimer formation (Amodeo, Rudolph, & Tong, 2007; Townley & Shapiro, 2007; Xiao et 
al., 2007), and the N-terminal domain of BamC, part of the β-barrel assembly machinery (Figure 
18) (R. Albrecht & Zeth, 2011). These structural homologs do not offer much insight into the 














Figure 18 Structural homologs of IntS9 and IntS11 CTDs. (a and b) Overlay of the IntS9 CTD (pink) with 
the C-terminal domain of an atypical Sm-like archaea protein [Protein Data Bank (PDB) ID code 1M5Q; 
Z-score 7.3; 17% identity] (gray) (a) and the platform subdomain of the AP-2 complex β subunit (PDB ID 
code 2IV9, Z-score 6.8; 4% identity) (b). (c–e) Overlay of the IntS11 CTD (green) with the KA1 domain 
of yeast Kcc4 (PDB ID code 3OSM; Z-score 7.9, 8% identity) (c), the C-terminal domain of the catalytic 
subunit of AMPK (PDB ID code 4EAK, Z-score 6.9, 16% identity) (d), and the N-terminal domain of 
BamC (PDB ID code 2YH6, Z-score 6.3, 10% identity) (e). From (Wu et al., 2017). 
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Section 2.3.5 Overall Structure of the IntS9-IntS11 CTD complex 
 
The complex of IntS9-IntS11 CTDs is formed by placing the β-sheets of the two domains 
side by side so that a parallel β-sheet is formed by strand β5 of IntS9 and strand β1 of IntS11. 
This juxtaposition creates a nine-stranded β-sheet in the IntS9-IntS11 CTD heterodimer. Most 
strands in this β-sheet are in antiparallel with only the two strands at the subunit interface being 
in parallel (Figure 19). The four flanking helices cover the same face of the β-sheet, whereas the 
other face of the β-sheet is exposed to the solvent (Figure 17b). Between the two β-strands at the 
center of the interface, there are seven hydrogen bonds formed (Figure 20a). In addition, many 
Figure 19 Topology diagram of the IntS9-IntS11 
CTD complex. The secondary structure of IntS9 
CTD is labeled in pink and the one of IntS11 CTD 
is labeled in green. Modified output from Pro-




side chains are also involved in the formation of the heterodimer, and ~1,200 Å2 of the surface 
area of each subunit is buried in this interface. The neighboring side chains of the two strands on 
the exposed face are in contact with each other.  The N-terminal helix (α1) of IntS11 contacts the 
N-terminal segment of IntS9, likely stabilizing both proteins in this region of the interface. 
 
 
Figure 20 Detailed interactions at the interface of the IntS9-IntS11 complex. (a) Hydrogen bonds between 
IntS11 β1 strand and IntS9 β5 strand are indicated by the dashed lines in red. The neighboring side chains 




On the other face of the β sheet, helix α2 of IntS9 and helix α3 of IntS11 are positioned 
next to each other. This allows favorable interactions among some of their side chains as well as 
side chains of the two β strands in the center of the interface (Figure 20b). Residues from the two 
β-strands are buried inside the interface and are mostly hydrophobic. Residues from the two 
helices are exposed to the solvent and are mostly hydrophilic or charged. Most of the residues at 
this interface are highly conserved among IntS11 and IntS9 homologs, especially near the center 
of the interface (Figure 21). 
Figure 21 Molecular surface of the IntS9-IntS11 CTD complex. (A) Molecular surface of the IntS9-
IntS11 CTD complex. Residues in the interface of IntS9 are colored in pink, and those in IntS11 are 
colored in green. The other residues are in gray.  (B) An "open-book" view of the IntS9-IntS11 interface 
showing the surface area of IntS11 in contact with IntS9 after 90° rotation around the vertical axis. (C) An 
"open-book" view of the IntS9-IntS11 interface showing the surface area of IntS9 in contact with IntS11 
after 90° rotation around the vertical axis. (D) Molecular surface of IntS11 colored by sequence 
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conservation produced by ConSurf (Armon, Graur, & Ben-Tal, 2001). Highly conserved residues are 
labeled. The color scheme runs from dark red (highly conserved) to cyan (poorly conserved) (color bar at 
bottom). (E) Molecular surface of IntS9 colored by sequence conservation. From (Wu et al., 2017). 
 
There are four copies of the IntS9-IntS11 CTD complex in the crystallographic 
asymmetric unit. The overall structures of the two subunits in the four complexes are similar, 
with rmsds of ~0.5Å for equivalent Cα atoms between any pair of them. The overall structures of 
the four complexes are similar as well, especially for the β-sheet and the four flanking helices 
(Figure 22). Several loop regions show large differences in the conformations, suggesting that 
these regions are somewhat flexible. We observed a disulfide bond formed by the two Cys542 
residues from two IntS11 subunits in neighboring complexes, which covalently links two 
complexes. The other cysteine residues in the structure are in the fully reduced state. Cys542 is 
located just before strand β2 in IntS11, there are some conformational differences observed in 
this strand among the four complexes. But since the disulfide bond creates only a small region of 
contact between two complexes, it is unlikely to affect the overall structure of the complex. This 
disulfide bond is likely the same disulfide bond we observed in Figure 11. We ran the protein 
solution samples and crystal samples on the non-reducing (w/o β-ME) SDS-PAGE (Figure 23). 
A minor amount of IntS11 CTD formed dimers in protein solution, while in the crystal, IntS11 
CTD proteins were dimers. The dimer band disappeared by adding DTT in the loading samples. 
It seems like the hIntS11 CTD proteins coincidently form dimers through the disulfide bond in 
solution without strong reducing agent. During crystallization, the dimerization of IntS9-IntS11 






Figure 22 Structural comparisons of the four copies of IntS9-IntS11 CTD complexes. (a). Overlay of the 
structures of the four IntS9-IntS11 CTD complexes. One complex is shown in color, and the other three in 
gray. Regions of large conformational differences among the four complexes are indicated with the red 
arrowheads. The α1 helix of IntS11 is missing in one of the subunits. (b). The two Cys542 residues from 
neighboring IntS11 subunits in the crystal are involved in a disulfide bond, and the two complexes are 
related by a non-crystallographic two-fold axis. One complex is shown in color and the other in gray. 
From (Wu et al., 2017). 
 
Figure 23 SDS-PAGE analysis of IntS9-IntS11 CTD complex in solution and in crystals. P, protein 
solution; C, crystal. +, 10 mM DTT; -, no DTT. 
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Section 2.3.6 Biochemical Studies of IntS9-IntS11 CTD complex 
 
To assess the structural observations on the IntS9-IntS11 CTD complex, we collaborated 
with the Wagner Lab in UTMB, where biochemcial and functional studies were conducted.  
 
Yeast two-hybrid assays 
Truncation mutants of IntS9 and IntS11 CTDs were made to map the regions that are 
required and sufficient to mediate the interaction. Residues 500-600 of IntS11 interacted strongly 
with IntS9 CTD, whereas residues 510-600 showed no interactions (Figure 24A). Residue 510 is 
located in the middle of strand β1 (Figure 20), indicating that this strand is important for the 
interaction. The helix α1 is outside the residues 500-600 range and was demonstrated to be 
dispensable for the interaction, which was consistent with its being located at the periphery of the 
interface. Deleting only 10 residues from the C terminus of IntS11 ( the mutant with residues 
500-590) abolished the interaction (Figure 24A), indicating the importance of the last helix α3 





Figure 24 Biochemical studies of the IntS9-IntS11 CTD complex. From (Wu et al., 2017). (A) Yeast two-
hybrid assay to define the minimal region of IntS11 sufficient to bind IntS9. AD, activation domain; BD, 
DNA-binding domain; VA, vector alone control. (B) Yeast two-hybrid assay to define the minimal region 
of IntS9 sufficient to bind IntS11. (C)Yeast two-hybrid assay using minimal regions of IntS9 and IntS11 
with structure-based mutations in IntS11. (D) Yeast two-hybrid assay using minimal regions of IntS9 and 
IntS11 with structure-based mutations in IntS9. (E) Coimmunoprecipitation of full-length myc-tagged 
wild-type and mutant IntS9 with full-length HA-tagged wild-type IntS11. Proteins bound to HA affinity 
resin were probed with anti-myc antibody by Western blot (WB). (F) Coimmunoprecipitation of full-
length myc-tagged wild-type and mutant IntS11 with full-length HA-tagged wild-type IntS9. (G) 
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Purification of endogenous INT from stable 293T cells expressing either wild-type FLAG-IntS11 or the 
interface mutant (R510P/T512P) using FLAG affinity resin. 
 
For IntS9, residues 579-658 interacted strongly with the IntS11 CTD, whereas residues 
589-658 showed no interactions with IntS11 CTD, indicating the requirement of strand β1 of 
IntS9 (Figure 24B). Deleting of 10 residues from the C terminus of IntS9 (residues 579-648) also 
abolished the interactions (Figure 24B). Residue 648 is located in the middle of helix α2, which 
was shown to interact with IntS11 in the structure. Overall, the minimal regions of IntS9 and 
IntS11 for sufficient interaction defined by yeast two-hybrid assays are fully consistent with the 
structural observations. 
We next designed a series of point mutations that are expected to perturb the IntS9-
IntS11 interaction based on the crystal structure. We mutated two residues in the middle of the 
each strand to prolines to disrupt the hydrogen bonds between the two β-strands at the center of 
the interface, i.e., the T633P/I635P double mutant for IntS9 (Figure 20b) and the R510P/T512P 
double mutant for IntS11 (Figure 20a). Mutations were also designed to disrupt interactions 
among side chains. We designed the R644E  single mutant, the R644E/R648E double mutant, 
and the R644E/R648E/L652A triple mutant in helix α2 of IntS9, the L509A/F511A double 
mutant in strand β1 of IntS11, and the L509A/F511A/E581R triple mutant in strand β1 and helix 
α3 of IntS11 (Figure 20b). Most of these residues are strictly conserved among the homologs, 
but Leu652 of IntS9 and Leu509 of IntS11 show conservative variations to other hydrophobic 
residues (Figure 10). We introduced these mutations into the minimal CTDs of IntS9 or IntS11 





The point mutations mentioned above were also introduced into the full-length cDNAs 
encoding IntS9 and IntS11 to test their impact on the interaction using a coimmunoprecipitation 
assay. Previous studies showed that IntS9-IntS11 heterodimer could withstand rigorous washing 
with detergent and high salt (T. R. Albrecht & Wagner, 2012). The same conditions were tested 
for mutants. Various myc-tagged IntS9 cDNAs with HA-tagged wild-type IntS11 were 
transfected into 293T cells. The cell lysates were subjected to anti-HA immunoaffinity matrix 
and probed with anti-myc antibodies using Western blot analysis. While the wild-type IntS9 was 
able to coimmunoprecipitate with IntS11, none of the mutants was detected in the 
immunoprecipitate (Figure 24E). As shown in the figure, all IntS9 mutants were expressed to the 
similar level to wide-type IntS9 which suggests that these proteins are folded properly and the 
lack of coimmunoprecipitation is caused by the disruption of the interaction by the mutations. 
The reciprocal coimmunoprecipitation were also performed where HA-tagged wild-type 
IntS9 with several IntS11 mutants were transfected into 293T cells. A catalytic mutant (E203Q, 
one of the conserved residue in the active site of the metallo-β-lactamase) was included as a 
control. Both the wide-type and the E203Q mutants were able to interact with IntS9, but the 
interface mutants did not show interaction (Figure 24F).  
To test whether disruption of IntS9-IntS11 interface could inhibit their ability to 
incorporate into the endogenous Integrator complex, cell lines stably expressing FLAG-tagged 
wild-type IntS11 or the mutant R510P/T512P IntS11 were created and the INT from cell extracts 
were purified by pulling down FLAG-tagged IntS11. The levels of IntS3, IntS4, IntS9 and 
IntS10 purified by mutant IntS11 were significantly lower than the levels of proteins purified by 
wild-type IntS11 (Figure 24G). These results demonstrate that the CTD interaction between 
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IntS9 and IntS11 is important to incorporate the IntS11 endonuclease into the endogenous INT. 
 
Section 2.3.7 Functional Importance of the IntS9-IntS11 Complex 
 
Currently there is no in vitro assay to assess INT function. To address the functional 
relevance of IntS9-IntS11 interactions observed in the crystal structure, in vivo UsnRNA 3'-end 
formation was measured by using a cell-based fluorescence reporter, the U7 snRNA gene 
reporter. This reporter consists of the human U7 snRNA promoter, the U7 snRNA gene body, a 
3'-box sequence for snRNA 3'-end processing, and the GFP coding gene followed by a strong 
polyadenylation signal (Figure 25A). When transfected into untreated cells, the reporter gives 
rise to no GFP signals, because the reporter is cleaved after the U7 snRNA gene due to normal 
3'-end processing by INT. If the INT subunits were knocked down by siRNA, the reporter is 
unable to be properly processed, resulting in transcriptional read-through and the production of a 
GFP mRNA containing the U7 snRNA as its 5' UTR. The GFP mRNAs are then translated using 
the native start codon of GFP because U7 lacks an AUG sequence. 
To do the RNAi rescue experiment, siRNAs targeting IntS9 or IntS11 were first 
transfected into HeLa cells to knock down endogenous IntS9 or IntS11. cDNA constructs of 
wild-type or interface mutant IntS9 or IntS11, containing silent point mutations that are RNAi-
resistant, were then transfected into IntS9- or IntS11-depleted cells. The expression level of GFP 
were detected to determine the effectiveness of the constructs in restoring INT activity. In 
control siRNA-treated cells, nearly no GFP was detected after transfection of U7-GFP reporter 
(Figure 25 B, C). In cells treated with siRNA targeting either IntS9 or IntS11, robust GFP 
proteins were detected. Expression of RNAi-resistant wild-type IntS9 or IntS11 was able to 
reduce the expression of GFP to the levels observed in control siRNA transfected cells. As 
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expected, expression of IntS11 catalytic mutant E203Q was unable to rescue U7 snRNA 
processing. The interface mutants also failed to rescue INT 3'-end processing activity (Figure 25 
B, C).  
Our collaborator also conducted rescue experiment on endogenous U2 and U4 snRNAs. 
They created stable cell lines expressing either RNAi-resistant wild-type IntS11 or a subset of 
IntS11 CTD interface mutants and assessed the levels of misprocessed U2 or U4 snRNA. About 
25-fold increase in the level of misprocessed snRNA was observed upon depletion of IntS11 
(Figure 25D). The levels of misprocessed snRNA present in IntS11 knockdown cells could be 
rescued by stably expressing wild-type IntS11, but the IntS11 CTD interface mutants could not 
reduce the levels of misprocessed snRNA.  
Collectively, these results demonstrate that interactions observed in the structure of 





Figure 25 Functional importance of the IntS9-IntS11 interactions for snRNA 3'-end processing. (A) 
Schematic diagram of U7-GFP reporter. (B) Western blot analysis of lysates from IntS9 depletion Hela 
cells that were transfected with myc-tagged RNAi-resistant wild-type or mutant IntS9. The U7-GFP 
reporter was transfected into all the cells. (C) Western blot analysis of lysates from IntS11 depletion Hela 
cells that were transfected with myc-tagged RNAi-resistant wild-type or mutant IntS11. The U7-GFP 
reporter was transfected into all the cells. (D) Quantitative RT-PCR analysis of misprocessed endogenous 
U2 or U4 snRNA. The bar graph represents the fold increase in the levels of misprocessed snRNA; error 
bars represent the SD from the mean. From (Wu et al., 2017). 
 
 
Section 2.4 Discussion 
 
The crystal structure of IntS9-IntS11 CTD complex reveals an extensive molecular 
interface mediated by numerous interactions which explains the high binding affinity that has 
been reported for IntS9 and IntS11. Although IntS11 has been identified as the endonuclease in 
INT, how IntS11 is recruited to the RNA substrates is not known. Based on the structure of its 
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analog CPSF-73, the endonucleolytic activity of IntS11 seems to be regulated by other protein 
factors from INT. The structure indicates a role for the catalytically inactive IntS9, which 
provides a distinct structural surface established only through the heterodimerization with 
IntS11. This specific interface may facilitate the recognition and recruitment of the active IntS11 
by other INT subunits. Such a mechanism might also be operative for CPSF-73 and CPSF-100 in 
the pre-mRNA 3'-end processing machinery.  
The homologous enzyme RNase J also has a CTD, but it is substantially smaller with one 
three-stranded β sheet and two facing α helices (de la Sierra-Gallay, Zig, Jamalli, & Putzer, 
2008). The CTD mediates homodimerization of RNase J in solution. Depletion of its CTD makes 
the enzyme monomeric and also abrogates all its activity in vitro even though its metallo-β-
lactamase and β-CASP domains remain intact. Based on the studies using U7-GFP reporter, it is 
clear the mutations specifically disrupting IntS9-IntS11 CTD heterodimerizations have effects 
equivalent to those of the catalytic mutation (E203Q) of IntS11. This finding demonstrates that 
the binding of IntS9 is essential for IntS11 function in cells. It also suggested that homo- or 
hetero-dimerization of β-CASP RNA endonucleases either plays an important role in the 
recruitment to RNA substrates or impacts the activity of the catalytic domain. One possible 
explanation is that formation of IntS9-IntS11 CTD complex would induce conformational 
changes in IntS11 that would allow access to and cleavage of the RNA substrates. This structural 
requirement would ensure that any IntS11 not associated with IntS9 would be inactive. Our 
results could not exclude the possibility that IntS11 may require additional factors for 
endonucleolytic activity. It is known that for 3’-end processing of either pre-mRNA or histone 
pre-mRNA, the cleavage activity of CPSF73 requires interaction with CPSF-100 as well as a 
scaffold protein called Symplekin (Michalski & Steiniger, 2015).  Recent studies has reported 
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the interaction between INT subunit 4 (IntS4) and IntS9-IntS11 heterodimer which is crucial for 
proper snRNA 3’-end processing (T. R. Albrecht et al., 2018). The efforts we made to 
understand the molecular basis for this interaction will be discussed in Chapter 4.  
IntS9 and IntS11 interaction are likely to be significant for assembly of INT. The CTD 
dimerization may provide an essential surface that is recognized by other members in the INT 
and facilitate the recruitment of the cleavage factor into the complex. This mechanism could 
regulate the cleavage event by ensuring that only the authentic IntS9-IntS11 heterodimer is 
incorporated into INT. This model is supported by our experiments that a heterodimer-deficient 
IntS11 failed to pull down other members of INT in addition to IntS9 (Figure 24G).  
We also noticed that between the metallo-β-lactamase domain and the CTD in IntS9 and 
IntS11 there are some unknown regions with secondary structure elements. These linkers are 
likely to be organized structurally. In the structure of RNase J, there is also a linker containing 
secondary structures between metallo-β-lactamase domain and the CTD. This linker interacts 
with both domains in RNase J (de la Sierra-Gallay et al., 2008). Similarly, the linkers in IntS9 
and IntS11 may also interact with both domains and communicate heterodimerization to the 
active site to activate cleavage. The exact arrangement of the catalytic domains, the linkers and 







Structural Studies of RNA deNADding enzyme Nudt12 
 
Section 3.1 Introduction 
 
In eukaryotes, the 5’-end of mRNA is modified by the addition of a 5',5'-triphosphate-
linked 7-methylguanosine (m7G) (cap 0 structure, Figure 26). The m7G cap plays a major role in 
various functional processes, including mRNA processing, nuclear export, cytoplasmic 
translation initiation (Ramanathan, Robb, & Chan, 2016). The m7G cap also functions as a 
protective group from 5' to 3' exonuclease cleavage.  Recently, a novel cap structure with 2'O 
methylation of +1 nucleotide (cap 1 structure, Figure 26) has been reported as an identifier of 
self RNA in the innate immune system against foreign RNA (Ramanathan et al., 2016). Some 
other derivatives of the canonical m7G cap have also been reported, including m2, 2, 7G-capped 
small U-rich noncoding RNAs with two additional methyl moieties to the guanosine (Mattaj, 
1986). Collectively , the different caps of RNA  provide a layer of regulation of 5’-end decay of 
eukaryotic RNAs. 
 
Figure 26 mRNA caps in eukaryotes. 
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RNA capping has been thought to occur only in eukaryotes for a long time. However, 
recent studies showed that the cofactor nicotinamide adenine dinucleotide (NAD) covalently 
links to the 5’-end of small regulatory RNA in bacteria in a cap-like manner and can protect the 
RNA from 5’-end decay by the bacterial RppH and RNaseE nuclease in vitro (Cahova, Winz, 
Hofer, Nubel, & Jaschke, 2015).  
In eukaryotes, the m7G cap is added to the 5’-end of mRNA cotranscriptionally when the 
RNA reaches a length of ~25 nucleotides(Moteki & Price, 2002). Addition of the NAD cap to 
bacterial RNA appears to occur during transcription initiation (Bird et al., 2016). NAD can be 
used by bacterial RNA polymerase in place of ATP as the first transcribed nucleotide (Bird et al., 
2016). In vitro assay showed that eukaryotic RNA polymerase II (RNAPII) can also use NAD as 
an initiating nucleotide (Bird et al., 2016), which raised the possibility of existence of NAD-
capped RNA in eukaryotes. Indeed, recent studies confirmed that NAD-capped RNAs are also 
present in eukaryotes, including Saccharomyces cerevisiae (Walters et al., 2017) and mammalian 
cells (Jiao et al., 2017). These findings demonstrate that NAD caps are broadly distributed in 
diverse organisms. 
In mammals, the m7G cap is removed by a subclass of Nudix (nucleoside diphosphate 
linked to another moiety X) hydrolase family of proteins, such as Dcp2, Nudt3 and Nudt16 
(Grudzien-Nogalska & Kiledjian, 2017), to initiate RNA 5’-end decay. The presence of NAD-
capped RNA in mammalian cells suggested that eukaryotic cells likely harbor enzymes that can 
remove NAD cap from an RNA. More recently, the mammalian non-canonical decapping 
enzyme, DXO, has been demonstrated to possess deNADding activity on NAD capped RNA 
(Jiao et al., 2017). It can decap the RNA by removing the entire NAD moiety to produce a 5’-end 
monophosphate RNA. The NAD-capped RNAs were more stable in cells lacking DXO, 
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indicating that this enzyme can modulate the levels of NAD-capped RNAs in cells (Jiao et al., 
2017). And different from prokaryotes, the NAD cap in mammalian cells seems to promote 
rather than prevent RNA decay since a synthetic NAD-capped RNA transfected into cells was 
less stable than m7G-capped RNA (Jiao et al., 2017).   
In prokaryotes, the NAD cap is removed by a nudix hydrolase protein named NudC 
(Cahova et al., 2015).  NudC was initially described as a NAD(H) pyrophosphohydrolase. It can 
remove the NAD cap by hydrolyzing the diphosphate linkage to produce nicotinamide 
mononucleotide (NMN) and 5' monophosphate RNA (Cahova et al., 2015). In vitro competition 
experiments showed that NudC prefers NAD-capped RNAs over NAD(H) by several orders of 
magnitude, suggesting that NAD-capped RNAs are its primary biological targets (Hofer et al., 
2016). The crystal structure of E. coli NudC showed that it contains three domains, an N-
terminal domain (NTD), a zinc-binding motif and a C-terminal domain (CTD) (Figure 27). The 
conserved Nudix sequence elements are located in CTD. 
Nudt12 is a mammalian Nudix hydrolase and a close homolog of bacterial NudC. The 
catalytic domain of Nudt12 shares 29% amino acid sequence identity with E. coli NudC. A 
unique feature of Nudt12 is the possess of an Ankyrin repeat domain in the N-terminal region 
(Figure 27). Nudt12 was identified as an NADH diphosphatase with a substrate preference for 
the reduced nicotinamide adenine dinucleotide (Abdelraheim, Spiller, & McLennan, 2003). At 
the beginning, Nudt12 was shown to localize to peroxisomes when fused to a C-terminal GFP 
(Abdelraheim et al., 2003), but recent immunocytochemistry reveals its presence in the 
cytoplasm in kidney cells (Carreras-Puigvert et al., 2017), which indicates its cytoplasmic 
function. Together, Nudt12 is a presumable deNADding enzyme in mammals. In order to 
demonstrate the deNADding activity of Nudt12 and understand its catalytic mechanism, we 
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determined the crystal structure of the catalytic domain of mouse Nudt12 in complex with the 
hydrolyzed product AMP.  Together with biochemical and functional studies, we prove that 
Nudt12 is a mammalian deNADding enzyme distinct from DXO. Our manuscript of this study is 
under review.  
 
 
Figure 27 Domains organization of mouse Nudt12 and E. coli NudC. The Ankyrin repeat domain of 
Nudt12 is indicated in gray, and the catalytic domain in green. The conserved Nudix motif in Nudt12 is 
indicated with a bar (green). 
 
 
Section 3.2 Experimental Procedures 
 
Protein Expression and Purification 
Residues 126-462 of wild-type mouse Nudt12 were sub-cloned into the pET28a vector 
(Novagen), and the recombinant protein carried an N-terminal His-tag. The purified protein did 
not produce any crystallization hits. The E219A/E220A/E221A triple mutation was introduced 
using Transfer-PCR method (Erijman, Dantes, Bernheim, Shifman, & Peleg, 2011). The mutant 
protein was expressed in Escherichia coli BL21(DE3) Star cells at 20℃ for 18 h. The cells were 
lysed by sonication in a buffer containing 20 mM Tris (pH 8.0), 250 mM NaCl, and 5% (v/v) 
glycerol. The lysate was loaded onto an Ni-NTA (Qiagen) column. The eluted protein was 
treated overnight with thrombin at 4℃ to remove the His-tag and was further purified by gel 
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filtration chromatography (Sephacryl S-300; GE healthcare). The purified protein was 
concentrated to 23 mg/ml in a solution containing 20 mM Tris (pH 8.0), 200 mM NaCl, and 5 
mM DTT before being flash-frozen in liquid nitrogen and stored at –80℃.   
 
Protein Crystallization 
The protein at 8 mg/ml concentration was incubated with 1.5 mM NAD (Sigma) in a 
buffer containing 20 mM Tris (pH 8.0), 200 mM NaCl, 5 mM DTT, and 2 mM MgCl2 at 4℃ for 
30 min. Crystals were obtained at 20℃ using the sitting-drop vapor-diffusion method. The 
reservoir solution contained 0.1 M HEPES (pH 7.5) and 24% (w/v) PEG2000MME. The crystals 
were cryo-protected by the reservoir solution supplemented with 15% (v/v) ethylene glycol and 
were flash-frozen in liquid nitrogen for data collection at 100K.   
     
Data Collection and Structure Determination 
X-ray diffraction data were collected using the Pilatus-6M detector at the Advanced 
Photon Source (APS) beamline 24-ID-C. The X-ray wavelength was 0.9791 Å. The diffraction 
images were processed and scaled using the XDS program (Kabsch, 2010). The crystal belonged 
to space group P1 with unit cell dimensions of a = 56.2 Å, b = 58.6 Å, c = 61.7 Å, α = 102.4°, β 
= 115.2°, γ = 104.7°. There is a Nudt12 homodimer in the crystallographic asymmetric unit.   
The catalytic domain of Nudt12 shares 29% sequence identity with NudC, and a 
molecular replacement solution could readily be found using the structure of NudC as the search 
model (Hofer et al., 2016) with the program Phaser (McCoy et al., 2007). However, the resulting 
electron density map was not of sufficient quality to rebuild the model. To obtain separate phase 
information, the CTD of Nudt12 was located using the molecular replacement method. The 
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phase information from this model was used to calculate an anomalous difference electron 
density map, which clearly revealed the positions of the two zinc atoms (with 11s peak heights), 
even though the diffraction data were collected far above the zinc absorption edge. Phase 
information from anomalous scattering was combined with that from the model, and the CTD 
could be rebuilt automatically using the resulting map with PHENIX (Adams et al., 2002a). 
Several b-strands in the NTD and segments near the zinc could be built manually with the 
program Coot (Emsley & Cowtan, 2004a) and were included in the subsequent structure 
refinement with PHENIX, which led to an improved 2Fo–Fc map. The entire structure was 
obtained after several rounds of manual model building followed by refinement. The 










































Data collection  
Space group P1 
Cell dimensions  
    a, b, c (Å) 56.2, 58.6, 61.7 
    α, β, γ(°) 102.4, 115.2, 104.7 
Resolution (Å)1 53-1.6 (1.69-1.6) 
Rmerge (%) 4.3 (65.3) 
CC1/2 0.999 (0.716) 
I/σI 11.5 (1.2)  
Completeness 89.6 (76.3) 
No. of observations 214,665 (27,577) 
Redundancy 2.8 (2.6) 
  
Refinement  
Resolution (Å) 53-1.6 
No. of reflections 76,425  
Rwork 18.0  
Rfree 21.9  
No. of atoms  
    Protein 4,969 
    Ligand/Ion 54 
    Water 290 
B-factors  
    Protein 39.3 
    Ligand/Ion 28.4 
    Water 38.8 
R.m.s. deviations  
    Bond lengths (Å) 0.015 
    Bond angles (°) 1.4 
The numbers in parentheses are for the highest resolution shell. 
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Section 3.3 Results and Discussion 
 
Section 3.3.1 Initial Constructs Design and Soluble Protein Expression 
 
Initially, three constructs were made using mouse Nudt12 gene (Table 5). The two 
truncated constructs were designed based on the sequence alignment with E. coli NudC, the 
structure of which has been solved. The truncated constructs include only the catalytic domain 
which is aligned with E. coli NudC. The Ankryin repeat domain was absent in the truncated 
constructs (Figure 28).  
Table 5 Initial mouse Nudt12 constructs 
Name Tag Vector Start End Total Residues M.W. (kDa) 
Nudt12-1 N-His pET28a 1 462 462 52 
Nudt12-2 N-His pET28a 126 462 337 39 
Nudt12-3 N-His pET28a 147 462 316 37 
 
        Two of the constructs, Nudt12-1 and Nudt12-2, could produce soluble proteins. Nudt12-3 
did not express maybe because it lacks an α helix that is important for protein folding. Both 
Nudt12-1 and Nudt12-2 proteins showed good behaviors and purity on gel filtration and SDS-




Figure 28 Sequence alignment of mouse Nudt12 and E. coli Nudc. Mm, Mus musculus; Ec, Escherichia 









Figure 29 Gel filtration profile of full-length mouse Nudt12. 
 
 
Section 3.3.2 Crystal Screening and Optimization 
 
The purified Nudt12 full-length protein and catalytic domain (residue 126-462) were 
screened for crystallization conditions with several commercial crystallization kits (Cudney et 
al., 1994; Jancarik et al., 1991) by sitting drop vapor diffusion at 20 ℃. The protein samples 
were incubated with 3' NADP with a molar ratio 1:5 (enzyme: substrate) before being used for 
crystallization. The full-length protein was crystallized from condition containing 4% v/v 
Tacsimate pH 7.0 and 12% w/v PEG 3350 (Figure 30). However, these tiny crystals did not 
diffract and were unable to be optimized. The truncated protein (residue 126-462) was 
crystallized from a different condition containing 1.4 M sodium malonate pH 6.0 (Figure 31). 
After optimization, we got bigger crystals from a condition with slightly different pH. But 








Figure 31 Crystals of Nudt12 catalytic domain (residue 126-462). A. A sitting drop from original 
screening. B. A sitting drop from optimization screening. 
 
To further optimize the crystals, we tried several methods including removing His-tag 
during purification, screening additives for crystallization, incubating the sitting drops under 
different temperature, and controlled dehydration. Unfortunately, the diffraction of the crystals 
could not go beyond 8-Å. We also made additional constructs around the initial constructs (Table 
6). Although most of these constructs produced soluble proteins, none of them could give 
crystals with good diffraction. 
We also tried to express and purify frog Nudt12 which shares 67% sequence identity 




Table 6 Additional Nudt12 constructs 
Name Tag Vector Start End Total Residues M.W. (kDa) 
Nudt12-4(E374Q) N-His pET28a 1 462 462 52 
Nudt12-5 N-His pET28a 9 462 454 51 
Nudt12-6 N-His pET28a 102 462 361 41 
Nudt12-7 N-His pET28a 44 462 419 47 
Nudt12-8 N-His pET28a 76 462 387 43 
Nudt12-9 C-His pET26b 126 462 337 39 
Nudt12-10(E374Q) N-His pET28a 126 462 337 39 
Nudt12-11 N-His pET28a 115 462 348 40 
Nudt12-12 N-His pET28a 121 462 342 40 
Nudt12-13 N-His pET28a 130 462 333 37 
Nudt12-14 N-His pET28a 135 462 328 37 
Nudt12-15 N-His pET28a 126 459 334 39 
Nudt12-16 N-His pET28a 115 459 345 40 
Nudt12-17 N-His pET28a 121 459 339 40 
Nudt12-18 N-His pET28a 130 459 330 37 
Nudt12-19 N-His pET28a 135 459 325 37 
Nudt12-20 N-His pET28a 279 462 184 21 
XlNudt12-1 N-His pET28a 1 458 458 53 
XlNudt12-2 N-His pET28a 122 458 377 38 
XlNudt12-3 C-His pET26b 1 458 458 53 
XlNudt12-4 C-His pET26b 122 458 337 38 
 
Section 3.3.3 Surface engineering of protein for crystallization 
 
Since the methods we mentioned above all failed to improve the quality of the crystals, 




Chemical Modification -- Reductive methylation of lysine residues 
Lysine is a basic residue with a long side chain. This kind of flexible, solvent-exposed 
amino acid side chain can be disruptive to a well-ordered crystal lattice. Reductive methylation 
of lysines that are on the exposed surface of the protein can reduce surface entropy and improve 
crystal packing (Walter et al., 2006). However, in our case, this method did not help improve 
diffraction of the crystals. 
 
Surface Entropy-reduction Genetic/Mutagenesis Approach   
This approach is to mutate large, charged residues on the surface of proteins in order to 
reduce the entropic cost of forming ordered intermolecular crystal contacts and thus enhancing 
the crystallizability of proteins. Typically, large and charged side chains, such as lysine and 
glutamate are mutated to small and uncharged side chains, like alanine (Derewenda & Vekilov, 
2006). The sites designed for mutagenesis were predicted by sequence analysis and the 
webserver, called SERp (Surface Entropy Reduction Prediction Server) (Goldschmidt, Cooper, 
Derewenda, & Eisenberg, 2007). The mutants made for this purpose are listed in Table 7. Most 
of the mutants did not effect the protein folding and produced soluble proteins except for 
Nudt12-24 (E294A/E295A, residue 126-462), which was completely insoluble. All of the soluble 
constructs were purified and used for crystallization screening. Although most of the constructs 
made no difference in crystallization, Nudt12-25 (E219A/E220A/E221A, residue 126-462) 
crystallized in a distinct condition from the previous ones that gave crystals. The condition 
contained 0.1 M HEPES pH 7.5 and 25% w/v PEG 2000MME. The crystal had a new shape 
which indicated a different packing. This crystal could diffract to 3-Å at home X-ray source. The 
reproduced crystals were able to diffract to 1. 6-Å at the Advanced Photon Source. The crystal 
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belonged to space group P1 with unit cell dimensions of a = 56.2 Å, b = 58.6 Å, c = 61.7 Å, 
α=102.4°, β = 115.2°, γ = 104.7°.  We were able to collect a 1.6-Å dataset for structure 
determination. 
Table 7 Surface entropy-reduction mutants 
Name Tag Vector Mutation Site Start End Total Residues 
Nudt12-21 N-His pET28a K166A/E167A 126 462 337 
Nudt12-22 N-His pET28a E192A/K193A 126 462 337 
Nudt12-23 N-His pET28a K261A/E262A 126 462 337 
Nudt12-24 N-His pET28a E294A/E295A 126 462 337 
Nudt12-25 N-His pET28a E219A/E220A/E221A 126 462 337 
Nudt12-27 N-His pET28a K261A/E262A 1 462 462 
Nudt12-28 N-His pET28a E294A/E295A 1 462 462 
Nudt12-29 N-His pET28a E219A/E220A/E221A 1 462 462 
Nudt12-30 N-His pET28a K105A/K106A 1 462 462 
 
Section 3.3.4 Structure Determination 
 
Although we collected a data set at 1.6 Å, the structure was not readily solvable. At the 
beginning, we tried molecular replacement using NudC as the search model. Using the program 
Phaser, we were able to find a solution. However, when we tried to build the model into the 
resulting electron density, we were only able to build in the CTD of Nudt12. The rest of the 
electron density is of poor quality maybe because those regions of Nudt12 share lower similarity 
with NudC.  
In the structure of NudC, there is a zinc-binding motif where a zinc ion coordinates with 
four conserved cysteine residues (Cys98, Cys101, Cys116, and Cys119). Based on sequence 
alignment, we found that there are also four conserved cysteine residues (Cys284, Cys287, 
Cys302, and Cys307) in the corresponding region of Nudt12, indicating a zinc motif. To 
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determine whether Nudt12 binds a zinc ion, the zinc content of purified Nudt12 was measured 
using PAR (4-(2-Pyridylazo) resorcinol disodium salt). The absorbance at 500 nm increased after 
adding Nudt12 to a solution containing PAR indicates the formation of a PAR2Zn2+ complex and 
the presence of zinc in Nudt12. Based on this information, we tried MR-SAD method to obtain 
more phase information from the original dataset. 
As mentioned above, the CTD of Nudt12 was able to be located using the molecular 
replacement method. Using the phase information of this model, we calculated an anomalous 
difference electron density map. Even though the diffraction data was collected far above the 
zinc absorption edge, the map still clearly showed the positions of two zinc atoms (with 11σ 
peak heights). Combining the phase information from anomalous scattering with that from the 
molecular replacement, we finally got the map good enough to rebuild the whole model. 
 
Section 3.3.5 Structural Insights into Nudt12 
 
The structure we determined includes the catalytic domain (residues 126-462) of mouse 
Nudt12 in complex with AMP and 3 Mg2+ ions (Figure 32). The refined atomic model has good 
agreement with the X-ray diffraction data and the expected geometric parameters. 98.7% of the 
residues are in favored region of the Ramachandran plot. Although the surface mutations 
(E219A/E220A/E221A) seem to be necessary for crystals to form, there is not much electron 
density around this region and we can not explain how these mutations affect the crystal packing. 
The Nudt12 catalytic domain consists of an N-terminal sub-domain (NTD, residue 126-
282), a zinc-binding motif (residues 283-318, where Zn is bound by four Cys side chains), and a 
C-terminal sub-domain (CTD, residues 319-462) (Figure 27). The conserved Nudix sequence 
elements are located in the CTD, whereas both NTD and CTD adopt a Nudix-fold. Like bacterial 
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NudC, the catalytic domain of Nudt12 forms a homodimer. All three sub-domains are involved 
in the dimerization and forms an extensive interface.   
 
Figure 32 Structure of Nudt12 catalytic domain. Two views of the crystal structure at 1.6 Å resolution of 
mouse Nudt12 catalytic domain in complex with AMP and 3 Mg2+ ions. The two monomers are colored 
green and cyan, respectively. AMP is shown as stick models in black, Mg2+ ions as pink spheres, and Zn 
as gray spheres. A disulfide bond between residues 177 and 247, formed during crystallization, is 
indicated as stick models.  
 
 
The conformations of the two monomers are essentially the same, with rms distance of 
0.46-Å for 303 aligned Cα atoms (Figure 33) . The overall structure of Nudt12 is similar to that 
of NudC, but there are also substantial differences between them, especially for the NTD (Figure 
33). The rms distance in Cα atoms for 226 aligned residues between Nudt12 and NudC is 2.0-Å. 




Figure 33 (a) Overlay of the structures of the Nudt12 monomers in complex with AMP (green and cyan) 
and Mg2+ (pink spheres) as well as NudC in complex with NAD (gray). (b) Overlay of the structures of 
the Nudt12 dimer (green and cyan for the two monomers) and the NudC dimer (gray). 
 
Although Nudt12 was co-crystallized with NAD, the solved structure showed clear 
density for AMP instead of NAD at the active site (Figure 34). AMP is the hydrolysis product of 
NAD by Nudt12. Our structure demonstrates that the construct (E219A/E220A/E221A, residues 
126-462) of Nudt12 we used for crystallization possesses catalytic activity. The adenosine is in 
the syn configuration and the adenine base is π-stacked with the side chain of Phe356 on one 
face and on the other face with the side chain of Tyr318 in the loop connecting the zinc-binding 
motif and the CTD of the other protomer (Figure 34). The hydroxyls of AMP are exposed to the 





        
Figure 34 (a) Detailed binding mode of AMP and Mg2+ ions in Nudt12. The coordination sphere of each 
metal ion is indicated with the red dashed lines. Water molecules are shown as red spheres. The omit Fo-
Fc electron density at 1.6 Å resolution for AMP, Mg2+ ions and their water ligands is shown in wheat 
color, contoured at 5 σ. (b) Comparison to the binding mode of NAD in NudC. Overlay of the structure of 
Nudt12 (in color) in complex with AMP (black) and the three Mg2+ ions (pink) with that of NudC in 
complex with NAD (gray). The position of the phosphate of AMP is separated by 5.4 Å from the 
equivalent phosphate of NAD, indicated with the black arrow. (c) Molecular mechanism of the 
deNADding reaction. A model of the binding mode of NAD is shown (salmon color). The AMP portion 
of the model is identical to the crystal structure, and the NMN portion is based on that in the NudC 
complex. The nucleophilic attack by the bridging ligand of Mg2 and Mg3 on the phosphate is indicated 
by the black arrow, which initiates the deNADding reaction. The water molecule that is displaced in the 
NAD complex is indicated with arrowhead (red). 
 
There is a large network of interactions between the phosphate group of AMP and 





One of the terminal oxygen atoms of the phosphate is a bridging ligand to Mg1 and Mg2, while a 
second terminal oxygen atom is coordinated to Mg3. Glu370, Glu374 and Glu415 in the Nudix 
motif are ligands of the Mg2+ ions. The main-chain carbonyl of Ala354 is coordinated to Mg1. 
Each Mg2+ is coordinated octahedrally, and the coordination spheres are completed by seven 
water molecules or hydroxide ions. One water molecule is a bridging ligand between Mg2 and 
Mg3 (Figure 34a). 
The binding mode of AMP in our structure has significant differences compared to that of 
the AMP portion of NAD in the complex with NudC (Figure 34b) (Hofer et al., 2016). The 
distance between the phosphorus atoms in the two structure is 5.4 Å (Figure 34b). This 
difference is probably due to the absence of metal ions in the NudC complex, so that the 
phosphate group is pushed away from the Glu side chains in the active site. In addition, the 
adenine is in the anti configuration in the NudC complex, and many residues in the active site 
region have different conformations as well, especially the residue equivalent to the Glu415 
ligand in Nudt12 (Figure 34b). A model for the binding mode of NAD to Nudt12 could be built 
based on the NMN portion of NudC-NAD structure (Figure 34c).  In this model, one of the water 
molecules in the current structure can be displaced by the terminal oxygen atom on the 
phosphate in NMN, and the oxygen atom can be directly coordinated to Mg1. 
The model of Nudt12-NAD complex provides clear molecular insights into the 
deNADding mechanism. The bridging hydroxide ion between Mg2 and Mg3 is located directly 
beneath the phosphate group of AMP, with a distance of 3.0 Å to the phosphorus atom (Figure 
34c). This hydroxide ion attacks the phosphorus atom and causes breakage of the pyrophosphate 
bond. The oxygen atom of AMP that is connected to the NMN is the leaving group. The 
oxyanion of the leaving group does not seem to be stabilized by a general acid in either Nudt12 
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or NudC. A solvent molecule might become bound in the presence of NAD and stablize the 
oxyanion of the leaving group. 
 
 
Section 3.3.6 In vitro Assay for Nudt12 deNADding Activity 
 
To test whether Nudt12 possesses deNADding activity, we collaborated with the 
Kiledjian Lab at Rutgers University. In humans, both Nudt12 and Nudt13 are reported with 
hydrolysis activity on free NAD. They both contain the SQPWPFPxS sequence motif found in 
the conserved Nudix domain common in NADH diphosphatases (Abdelraheim et al., 2003; Frick 
& Bessman, 1995). To test their deNADding activity in vitro, mouse Nudt12 or Nudt13 was 
incubated with either 32P labeled NAD (Nicpp*A; asterisk denotes 32P label) or in vitro 
transcribed 32P labeled RNA capped with NAD (Nicpp*A-RNA). Both Nudt12 and Nudt13 can 
hydrolyze free NAD into NMN (Nicp) and AMP (p*A) which can be detected by thin-layer 
chromatography (TLC) (Figure 35a). To determine whether these proteins can hydrolyze NAD-
RNA, the reaction products were further treated with nuclease P1, which cleaves all 
phosphodiester bonds within an RNA and release the detectable labeled p*A. Based on the 
results, Nudt12 possessed NAD cap deNADding activity in vitro, whereas Nudt13 could not 
hydrolyze NAD-capped RNA (Figure 35b). The results showed that Nudt12 cleaved the NAD-
capped RNA between the diphosphate linkage, similar to the activity observed with NudC 
(Cahova et al., 2015) and distinct from that of DXO (Jiao et al., 2017), which is consistent with 
the molecular insights observed from the structure. The Nudt12 decapping activity on m7G-
capped RNA was also compared to the deNADding activity on NAD-capped RNA. The result 
showed that Nudt12 has greater deNADding activity than decapping activity (Figure 35c). As the 
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structure shows, the glutamate residues in the active site of Nudt12 are crucial for the hydrolysis. 
Mutating two glutamate residues in the active site into glutamine abolished the deNADding 




Figure 35 Mouse Nudt12 deNADding activity in vitro. Nic denotes nicotinamide. The line represents the 
RNA. (a) Mouse Nudt12 and Nudt13 enzymatic activity on 32P-labeled free NAD+ (Nicpp*A). (b) Mouse 
Nudt12 and Nudt13 enzymatic activity on 32P-labeled NAD+ -capped RNA (Nicpp*A------). (c) In vitro 
decapping/deNADding assays with Mouse Nudt12 and indicated 32P-cap-labeled substrates. N12E/Q 
represents the catalytically inactive double-mutant Nudt12 E373Q/E374Q. 
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Section 3.3.7 Comparison of the Active Site of E. coli RppH with that of Nudt12 
 
We compared the active site of Nudt12 with that of E. coli RppH (RNA 
pyrophosphohydrolase, (Deana, Celesnik, & Belasco, 2008; Vasilyev & Serganov, 2015)) and 
found that the binding mode of the Mg2+ ions and the reaction mechanism of the two proteins are 
generally similar. For RppH, an Arginine residue (Arg8) stabilizes the oxyanion of the leaving 
group (Figure 36). The RppH Arg8 is equivalent to Asp322 in Nudt12 (Figure 34a), and its 
guanidinium group would clash with the side chain of Phe356 in Nudt12 (Figure 36). Unlike 




Figure 36 Comparison to the substrate binding mode and reaction mechanism of RppH. The structure of 
RppH in complex with pppRNA is shown (Serganov, 2015), in the same orientation as that for Nudt12 
(Figure 34c). Residue Phe356 in Nudt12 is shown (green), clashing with the side chain of Arg8 in RppH. 
 
Section 3.3.8 E. coli RppH Possesses RNA deNADding Activity in vitro 
 
E. coli RppH was reported to have no hydrolytic activity on NAD-capped RNA (Cahova 
et al., 2015). So RppH was initially used as a negative control in the assays to determine Nudt12 
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and NudC in vitro hydrolysis activity on NAD, NAD-capped RNA and m7G-capped RNA. 
Surprisingly, although the bacterial RppH could not hydrolyze free NAD, it showed robust 
deNADding activity on NAD-capped RNA (Figure 37a). The disagreement with previous reports 
may be caused by different in vitro parameters and/or different substrate RNA sequences 
employed in the two studies. RppH removes the NAD cap by hydrolyzing within the diphosphate 
bond, which is similar to the activity of Nudt12 and NudC. The in vitro assay indicates that 
RppH is a potential deNADding enzyme in bacteria. 
The deNADding activity of RppH might be interpreted by modeling NAD into RppH 
active site. The binding mode for NAD in RppH would not be the same as the one in Nudt12 
because the nicotinamide portion would clash with the protein. The binding mode of pppRNA to 
RppH suggested that a folded conformation of NAD (Figure 37b) could fit in the RppH active 
site. The adenine nucleotide of NAD would assume a conformation similar to that of the first 
nucleotide of pppRNA. The nicotinamide of NAD could have cation-π interactions with Arg8 of 
RppH. The RNA body could bind RppH in the same way for deNADding as for PPH activity. It 
is reported that the pyrophosphohydrolase acitivity of E. coli RppH has a preference for a 
guanine at the second position of the substrate (Vasilyev & Serganov, 2015), suggesting that the 
deNADding activity would prefer a guanine nucleotide at the first position of the substrate RNA. 
This model also suggests that RppH is only active on NAD-RNA rather than NAD alone because 






Figure 37 RppH has RNA deNADding activity in vitro. (a) In vitro decapping assays of RppH, NudC and 
Nudt12 with 32P-labeled substrates: free NAD (left panel), NAD-capped RNA (middle panel) and m7G-
capped RNA (right panel). (b) A model for the binding mode of NAD to RppH and the molecular 
mechanism for its deNADding activity. The AMP portion is based on the first nucleotide of pppRNA 
(gray) in RppH. The amide group of nicotinamide could be recognized by hydrogen-bonding interactions 







Section 3.3.9 In vivo Assays for Nudt12 deNADding Activity 
 
The first assay to determine Nudt12 function in mammalian cells is to test whether the 
stability of NAD-capped RNAs is altered in the absence of Nudt12. HEK293T cell lines with 
individual or double knockout of Nudt12 or DXO gene were generated by CRISPR/Cas9n 
(Figure 38a). 32P labeled NAD-capped transcripts or m7G-capped transcripts were transfected 
into the knockout HEK293T cell lines. After transfection, RNAs were harvested and detected 
over the time course. As shown in Figure 38b, NAD+-capped RNAs were more stable in N12-
KO (Nudt12 knockout) than in control cells. In contrast, m7G-capped RNA showed similar half 
life in both cell line backgrounds (Figure 38c), which indicates that Nudt12 modulates the 






Figure 38 The stability of NAD+-capped RNA in Nudt12 knockout cells. (a) Western blot of Nudt12 and 
DXO protein levels in HEK293T control knockout (Con-KO), Nudt12 knockout (N12-KO), DXO 
knockout (DXO-KO) or double knockout (N12:DXO-KO) cell lines. GAPDH was used as an internal 
control. (b) Remaining 32P labeled NAD+-capped RNAs, or (c) m7G-capped RNAs after transfection into 
knockout HEK293T cells.   
 
The second assay is to determine whether Nudt12 regulates expression of endogenous 
NAD-capped RNA in cells. The approach used here to detect en masse NAD caps is called 
NAD-CapQ (Figure 39a). This approach combines enzymatic properties of Nuclease P1 with a 
colorimetric NAD/NADH Quantitation to detect total NAD and NADH levels. RNA from Con-
KO or N12-KO cells were measured by NAD-CapQ. In N12-KO cells, a 1.5-fold increase in 
total NAD-capped RNA was detected compared to the control (Figure 39b). A similar increase 
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was observed in DXO-KO cells as well (Figure 39b). The cell line harboring a double knockout 
of both Nudt12 and DXO (N12: DXO-KO; Figure 38a) resulted a 2.7-fold higher level of NAD 
caps compared to Con-KO cells (Figure 39b). These data demonstrated that in addition to DXO, 
Nudt12 is also a deNADding enzyme in cells. Since the double knockout of both Nudt12 and 
DXO resulted in the highest level of NAD-capped RNA, the two enzymes appear to function on 
distinct NAD-capped RNA substrates. 
 
Figure 39 Nudt12 regulates the level of endogenous NAD-capped RNA in cells. (a) Schematic of NAD-
CapQ assay. (b) NAD-capped RNA levels in different knockout cells. 
 
Section 3.3.10 Nudt12 Preferentially Targets a Subset of mRNAs for deNADding 
The knockout results shown in Section 3.3.9 indicates that Nudt12 may preferentially 
target a subset of NAD-capped mRNA for deNADding. To further test this hypothesis, our 
collaborator utilized the NAD captureSeq approach to identify NAD-capped RNAs enriched in 
HEK293T N12-KO cells. The result showed that 188 NAD-capped RNAs were specifically 
enriched in the N12-KO cells. These enriched RNAs belong to five major pathways, three 
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biological process (BP) terms and two cellular compartment (CC) terms (Figure 40). One of 
these is associated with rRNA processing while the remaining are linked with mitochondrial 
metabolism or translation. The mRNA enriched in N12-KO cells are primarily involved in 
respiratory functions, which suggests an interaction between cell metabolism and Nudt12 
decapping of NAD-capped transcripts. 
To further validate Nudt12 targeted RNAs, 12 RNAs (5 RNAs in oxidative 
phosphorylation, 7 random RNAs) were chosen for direct quantitative reverse-transcription 
(qRT)-PCR (Figure 41). Among the 12 RNAs, 11 were validated by direct qRT-PCR. CKS2 
mRNA was not a target of Nudt12 based on NAD captureSeq, and qRT-PCR showed no change 
of CKS2 RNA level in N12-KO cells compared to WT cells. Seven of the qRT-PCR validated 
genes (COX17, MRPL15, MRPS23, NDUFAF4, NDUFB2, NDUFB9, and NDUFS3) were 
found in the enriched GO terms in Figure 40. All together, we verified Nudt12 as a deNADding 
enzyme in cells and the RNAs enriched in N12-KO cells suggest a role for Nudt12 in NAD-
capped transcripts encoding proteins with mitochondrial functions. 
mRNAs enriched in N12-KO cells were relatively distinct from those enriched in DXO-
KO cells (Jiao et al., 2017). Only 13 out of the 188 mRNAs found enriched in N12-KO cells 
overlap the 67 mRNAs enriched in DXO-KO cells. The hierarchical clustering of all 242 
transcripts by replicate samples indicates different patterns of transcripts enriched in Nudt12 or 
DXO (Figure 41). The Nudt12-enriched GO terms are similarly distinct from DXO-enriched GO 
terms, highlighted in the left colorbar (Figure 41). A major class of NAD-capped RNAs enriched 
exclusively in N12-KO cells is involved in mitochondrial metabolism. In contrast, the most 
prominent NAD-capped RNAs elevated in DXO-KO cells are the small nucleolar RNAs 
(snoRNAs) and the related small Cajal body RNAs (scaRNAs) (Jiao et al., 2017) (Figure 41), 
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which did not increase in cells lacking Nudt12. NAD-capped mRNA involved in oxidative 
phosphorylation were also specifically enriched in N12-KO cells (Figure 41). These analyses 
revealed that there are NAD-capped RNAs regulated by Nudt12 or DXO in mammalian cells. 
Each deNADding enzyme targets a distinct subset of mRNAs. 
 
Figure 40 Top gene ontology (GO)-biological process (BP) and cellular component (CC) terms enriched 
with 188 genes increased in Nudt12-KO over control (FDR<5%; > 2-fold increased, and > 1 FPKM in 






Figure 41 Nudt12 preferentially targets a subset of mRNAs for deNADding. (a) qRT-PCR validation of 
NAD-capped mRNAs in N12-KO cells. Data are presented relative to the HEK293T Con-KO cells and 
set to 1. Error bars represent ± SD. p values are denoted by asterisks; (***) p< 0.001 (Student's t test). (b) 
A Venn Diagram of NAD-capped RNAs enriched in N12-KO and DXO-KO cells (≥2-fold, ≤5% FDR, >1 
FPKM in HEK293T WT cells). (c) Heatmap of mRNAs enriched in either N12-KO or DXO-KO. The 
color bar at left indicates enriched gene groups, either from top GO biological processes (Figure 40) or 
presence of major gene families as indicated (Hist: histones, SNO/SCA: snoRNAs or scaRNAs). The 
color bar at right indicates membership in components of Venn diagram (Figure 41b). For each mRNA in 
the heatmap, green indicates relative enrichment, red indicates relative depletion, with expression 
normalized for each mRNA across all samples to indicate relative differences. Individual replicates 







Section 3.4 Discussion 
 
The NAD-capped RNA has been demonstrated to exist not only in prokaryotes but also 
eukaryotes. The evolutionary conservation of the noncanonical NAD cap implies a function in 
RNA metabolism. In mammalian cells, there are multiple m7G cap decapping enzymes 
(Grudzien-Nogalska & Kiledjian, 2017). Our studies demonstrated there are also multiple 
deNADding enzymes in cells. In mammalian cells, in addition to DXO, Nudt12 Nudix hydrolase 
is also a deNADding enzyme and targets a distinct subset of mRNA for deNADding. The crystal 
structure of mouse Nudt12 catalytic domain (residue 126-462) defines the binding mode of the 
AMP product and the three coordinated magnesium ions. The structure provides detailed insights 
into the molecular mechanism of deNADding reaction. Different from DXO that releases an 
intact NAD, Nudt12 hydrolyzes the diphosphate bond within the NAD to release NMN from 
NAD-capped RNA. A major class of NAD-capped RNA that were regulated by Nudt12 are 
involved in mitochondrial metabolism which supports a correlation between Nudt12 deNADding 
activity and cellular energetics.  
          The identification of Nudt12 and E. coli RppH as deNADding enzymes indicates that there 
are at least three classes of deNADding enzymes. The first is the DXO family of proteins that 
remove the intact NAD from the 5’-end of the capped RNA (Jiao et al., 2017). The second is 
Nudt12/NudC-like proteins that cleave within the pyrophosphate of both NAD and NAD-capped 
RNA. The third one contains RppH, which does not hydrolyze NAD, but can cleave NAD-
capped RNA. In mammalian cells, DXO and Nudt12 target different subsets of RNA substrates 
for deNADding. The question how these enzymes differentiate between different RNAs for 
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specific deNADding remains unknown. One possibility is that deNADding enzymes can 
selectively bind to the 5’-end of specific RNAs. The other possibility is that NAD-RNA is 
specifically recognized by different RNA-binding proteins. The deNADding enzyme might later 
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The metazoan Integrator complex (INT) has important functions in
the 3′-end processing of noncoding RNAs, including the uridine-
rich small nuclear RNA (UsnRNA) and enhancer RNA (eRNA), and in
the transcription of coding genes by RNA polymerase II. The INT
contains at least 14 subunits, but its molecular mechanism of ac-
tion is poorly understood, because currently there is little struc-
tural information about its subunits. The endonuclease activity of
INT is mediated by its subunit 11 (IntS11), which belongs to the
metallo-β-lactamase superfamily and is a paralog of CPSF-73, the
endonuclease for pre-mRNA 3′-end processing. IntS11 forms a sta-
ble complex with Integrator complex subunit 9 (IntS9) through
their C-terminal domains (CTDs). Here, we report the crystal struc-
ture of the IntS9–IntS11 CTD complex at 2.1-Å resolution and de-
tailed, structure-based biochemical and functional studies. The
complex is composed of a continuous nine-stranded β-sheet with
four strands from IntS9 and five from IntS11. Highly conserved
residues are located in the extensive interface between the two
CTDs. Yeast two-hybrid assays and coimmunoprecipitation exper-
iments confirm the structural observations on the complex. Func-
tional studies demonstrate that the IntS9–IntS11 interaction is
crucial for the role of INT in snRNA 3′-end processing.
snRNA processing | protein complex | integrator complex
The Integrator complex (INT) was originally characterized asan important factor for U-rich small nuclear RNA (UsnRNA)
3′-end processing and as a binding partner for phosphorylated
RNA polymerase II (Pol II) (1–3). Since then it also has been
found to participate in Pol II transcription initiation, pause re-
lease, elongation, and termination at protein-coding genes (4–6),
thereby broadening the scope of INT function. Most recently INT
was shown to be important for enhancer RNA (eRNA) 3′-end
processing as well (7). The physiological importance of INT is
reflected by its involvement in other cellular processes, such as
embryogenesis (8), ciliogenesis (9), adipose differentiation (10),
human lung function (11), and maturation of herpesvirus micro-
RNA 3′ ends (12).
The INT contains at least 14 subunits (IntS1 through IntS14),
ranging from 49 to 244 kDa, and the mass of the full complex is
more than 1 million daltons. Despite its functional importance,
INT is poorly understood at the molecular level, and currently
there is very little structural information for any of its subunits.
Moreover, the majority of the INT subunits share little sequence
homology with other proteins and have few recognizable do-
mains, making it difficult to predict the function and the mech-
anism of the subunits (2).
Two INT subunits that do share significant sequence conser-
vation with other proteins are IntS9 and IntS11 (1, 2). Most
importantly, IntS11 is a close homolog of CPSF-73 (cleavage and
polyadenylation specificity factor, 73 kDa), the endonuclease for
the pre-mRNA 3′-end processing machinery (13–16). Similarly,
IntS11 is the endonuclease subunit for INT, responsible for the
cleavage reaction at the 3′ end of target RNAs (1, 2). CPSF-
73 and IntS11 belong to the metallo-β-lactamase superfamily of
proteins (17). The metallo-β-lactamase domain of each protein
contains conserved amino acids that coordinate metal ions for
catalysis (Fig. 1A and Fig. S1) (18). CPSF-73, IntS11, and their
close homologs also have a β-CASP domain (named after its
founding members: CPSF73, Artemis, SNM, and PSO), which is
an insert in the metallo-β-lactamase domain (Fig. 1A). The active
site is located at the interface between the two domains, and
therefore the β-CASP domain likely regulates substrate access to
the active site. The metallo-β-lactamase and the β-CASP do-
mains of human IntS11 (residues 1–450) (Fig. S1) and CPSF-
73 share 40% amino acid sequence identity, indicating their high
degree of sequence conservation and underscoring the impor-
tance of these two domains.
The CPSF complex also contains an inactive homolog of
CPSF-73, CPSF-100, in which several of the active-site residues
have been changed during evolution. Likewise, IntS9 is the in-
active homolog of IntS11 in INT (Fig. 1B and Fig. S2). The se-
quence conservation between IntS9 and CPSF-100 is weaker,
and IntS9 has two inserted segments in the metallo-β-lactamase
domain (Fig. 1B). The functional roles of IntS9 and CPSF-100 in
their respective complexes remain to be clarified.
IntS9, IntS11, CPSF-73, and CPSF-100 all contain a C-terminal
domain (CTD) beyond their metallo-β-lactamase and β-CASP
domains (Fig. 1). However, the sequence conservation for
these domains is much poorer. We showed previously that the
CTDs of IntS9 and IntS11 are required and sufficient to mediate
their association, suggesting that these domains ensure specific
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heterodimerization of the two subunits, thereby compartmen-
talizing INT from CPSF (19). However, the molecular basis for
this association is not known. Currently available dimer struc-
tures of other β-CASP homologs (20–23) do not provide any
insights into the IntS9–IntS11 heterodimer, nor are structures
available for the CPSF-73/CPSF-100 CTDs.
We have determined the crystal structure of the IntS9–IntS11
CTD complex at 2.1-Å resolution. The structure is composed of
a continuous nine-stranded β-sheet, with four strands from
IntS9 and five from IntS11. Four helices cover one face of this
β-sheet, and the other face is exposed to solvent. Highly con-
served residues are located in the extensive interface between
the two CTDs formed by the two neighboring strands and two
helices. We designed truncation and site-specific mutants based
on the structure, and both our yeast two-hybrid assays with the
CTDs and coimmunoprecipitation experiments with the full-
length proteins confirm the structural observations on the com-
plex. Finally, we demonstrated that mutations that disrupt the
IntS9–IntS11 interaction also abolish U7 snRNA 3′-end pro-
cessing, indicating that this interaction is crucial for the function
of the Integrator complex.
Results
Structures of the IntS9 and IntS11 CTDs. The crystal structure of the
complex of IntS9 and IntS11 CTDs has been determined at 2.1-Å
resolution. The atomic model has good agreement with the
X-ray diffraction data and the expected geometric parameters
(Table S1). Of the residues, 98.1% are in the favored region of
the Ramachandran plot, and no residues are in the disallowed
region.
The structure of the IntS9 CTD (covering residues 582–658)
(Fig. 1B) contains a four-stranded, antiparallel β-sheet (β2–β5)
(Fig. 1C). Two helices (α1–α2), formed by residues just before
and after the β-sheet, cover one of its faces (Fig. 1D). A two-
stranded antiparallel β-sheet (β1, β6) formed by residues near the
beginning and end of the domain likely provides further stability
to this domain.
The structure of the IntS11 CTD (covering residues 493–596)
(Fig. 1A) contains a five-stranded antiparallel β-sheet (β1–β5)
with two helices on one of its faces (α2-α3) (Fig. 1C). A short
helix (α1) precedes the first β-strand and is partly stabilized by
interactions with IntS9 (see next section).
The up–down organization of the last four strands (β2–β5) of
the IntS11 CTD is similar to that for the β-sheet in IntS9 CTD.
In fact, the two structures can be superposed with an rmsd of
2.4 Å for 64 equivalent Cα atoms (Fig. 1E), although the sequence
identity between the two proteins in this region is only 16%. The
two helices covering the β-sheet are located at similar positions in
the two structures as well. A unique feature of IntS11 is strand β1,
which is the longest strand in the structure and is located in the
center of the interface with IntS9.
Close structural homologs for IntS9 CTD include the CTD of
an atypical Sm-like archaeal protein (24) and the platform sub-
domain of the AP-2 complex β subunit (Fig. S3) (25), based on a
DaliLite search (26). Close structural homologs for IntS11 CTD
include the kinase associated-1 domain (KA1 domain) at the C
terminus of yeast septin-associated kinases and human MARK/
PAR1 kinases (27), the C-terminal domain of the catalytic subunit
of AMP-activated protein kinase (AMPK, SNF1 in yeast) that
mediates heterotrimer formation (28–30), and the N-terminal
domain of BamC, part of the β-barrel assembly machinery (Fig.
S3) (31). These structural homologs do not offer much insight into
the functions of the two CTDs.
Crystal Structure of the IntS9–IntS11 CTD Complex. The complex of
IntS9–IntS11 CTDs is formed by juxtaposing the β-sheets of the
two domains, such that strand β5 of IntS9 forms a parallel
β-sheet with strand β1 of IntS11 (Fig. 1C). This juxtaposition
creates a nine-stranded, mostly antiparallel β-sheet in the IntS9–
IntS11 CTD heterodimer, with only the two strands at the sub-
unit interface being in parallel. The four flanking helices cover
the same face of this β-sheet, and the other face of the β-sheet is
open to the solvent (Fig. 1D). Seven hydrogen bonds are formed
between the two β-strands at the center of the interface (Fig.
2A). In addition to these interactions, many side chains mediate
the formation of this heterodimer as well, and ∼1,200 Å2 of the
surface area of each subunit is buried in this interface (Fig. 3
A–C). The neighboring side chains of the two strands on the
exposed face of the β-sheet are in contact with each other. In
addition, the N-terminal helix (α1) of IntS11 contacts the
N-terminal segment of IntS9, likely stabilizing both proteins in
this region of the interface (Fig. 2A).
On the other face of the β-sheet, helix α2 of IntS9 and helix
α3 of IntS11 are positioned next to each other, allowing favor-
able interactions among some of their side chains as well as the
side chains of the two β-strands in the center of the interface
(Fig. 2B). Residues from the two β-strands are mostly hydro-
phobic in this part of the interface, whereas those from the two
helices are mostly hydrophilic or charged. Most of the residues at
this interface are highly conserved among IntS11 (Fig. 3D and
Fig. S1) and IntS9 (Fig. 3E and Fig. S2) homologs, especially
near the center of the interface.
Fig. 1. Crystal structure of the human IntS9–IntS11 CTD complex. (A) Do-
main organizations of human IntS11 and CPSF-73. The metallo-β-lactamase
and β-CASP domains are shown in cyan and yellow, respectively. The
conserved residues in the active site are indicated by red lines. The CTD
of IntS11 is shown in green. CPSF-73 also has a CTD, but its sequence is
highly divergent from that of IntS11, and its exact boundary is not known.
(B) Domain organizations of human IntS9 and CPSF-100. The CTD of
IntS9 is shown in pink. An insert in the β-CASP domain of CPSF-100 and
two inserts in the metallo-β-lactamase domain of IntS9 are shown in gray.
(C) Structure of the human IntS9–IntS11 CTD complex. The IntS9 CTD is in
pink, and the IntS11 CTD is in green. (D) Structure of the human IntS9–
IntS11 CTD complex, viewed after 90° rotation around the horizontal axis.
(E ) Overlay of the structure of the IntS9 CTD (pink) with the structure of the
IntS11 CTD (green). The structure figures were produced with PyMOL
(www.pymol.org).









There are four copies of the IntS9–IntS11 CTD complex in the
crystallographic asymmetric unit. The overall structures of the
two subunits in the four complexes are similar, with rmsds of
∼0.5 Å for equivalent Cα atoms between any pair of them. The
overall structures of the four complexes are similar as well, espe-
cially for the β-sheet and the four flanking helices (Fig. S4).
However, there are large differences in the conformations of sev-
eral of the loops, suggesting that these regions are somewhat
flexible. In addition, the Cys542 residues from two IntS11 subunits in
neighboring complexes form a disulfide bond covalently linking two
complexes (Fig. S4), and this disulfide linkage is likely a crystalli-
zation artifact. The other cysteine residues in the structure are in
the fully reduced state. Cys542 is located just before strand β2 in
IntS11, and some conformational differences in this strand are
observed among the four complexes (Fig. S4). It is unlikely that
this disulfide bond affects the overall structure of the complex,
because it creates only a relatively small region of contact between
two complexes (Fig. S4).
Biochemical Studies Confirm the Structural Observations. To assess
the structural observations on the IntS9–IntS11 CTD complex,
we carried out yeast two-hybrid assays to evaluate interactions
between different variants of the two CTDs as well as coimmu-
noprecipitation experiments with the full-length proteins. We
previously demonstrated that using yeast two-hybrid assay to
characterize the interaction between IntS9 and IntS11 is re-
markably robust, because binding could be detected even when
3-amino-1,2,4-triazole is present at a 100-mM concentration
(32). We carefully mapped the regions within the CTDs of
IntS9 and IntS11 that are both required and sufficient to mediate
their interaction. We created a series of truncation mutants,
removing 10 amino acid residues at a time, and found that res-
idues 500–600 of IntS11 interacted strongly with IntS9 CTD,
whereas residues 510–600 showed no interaction (Fig. 4A).
Residue 500 is located near the end of helix α1, and residue
510 is in the middle of strand β1 (Fig. 1C), indicating the im-
portance of β1. This assay also determined that helix α1 of
IntS11 is not required for the interaction, as is consistent with its
being located at the periphery of the interface. On the other
hand, deleting only 10 residues from the C terminus of IntS11
(resulting in a variant with residues 500–590) abolished the in-
teraction (Fig. 4A). Residue 590 is located in the last turn of helix
α3, confirming its importance for the IntS9–IntS11 interaction.
Similarly, we found that residues 579–658 of IntS9 interacted
strongly with the IntS11 CTD, whereas residues 589–658 showed
no interactions (Fig. 4B). Residue 579 is before the first residue
observed in the current structure, and residue 589 is just after
strand β1 (Fig. 1C). Deleting 10 residues from the C terminus of
IntS9 (579–648) also abolished the interaction (Fig. 4B). Residue
648 is located in the middle of helix α2. Overall, the results from
the truncation mutants define the minimal regions of IntS9 and
IntS11 that are important for their interactions; these results are
fully consistent with the structural observations.
We next designed a series of point mutations that are expected
to perturb the IntS9–IntS11 interaction based on the structural
observations. To perturb the hydrogen-bonding interactions be-
tween the two β-strands in the dimer interface, we mutated two
residues in the middle of each strand to proline, i.e., the T633P/
I635P double mutant for IntS9 (Fig. 2B) and the R510P/T512P
double mutant for IntS11 (Fig. 2A). We also designed mutations
to disrupt interactions among the side chains, including the
R644E single mutant, the R644E/R648E double mutant, and
the R644E/R648E/L652A triple mutant in helix α2 of IntS9, the
L509A/F511A double mutant in strand β1 of IntS11, and the
L509A/F511A/E581R triple mutant in strand β1 and helix α3 of
IntS11 (Fig. 2B). Most of these residues are strictly conserved
among the homologs, whereas Leu652 of IntS9 and Leu509 of
IntS11 show conservative variations to other hydrophobic residues
(Figs. S1 and S2). We introduced these mutations into the
Fig. 2. Detailed interactions at the interface of the IntS9–IntS11 CTD com-
plex. (A) Hydrogen-bonding interactions between strand β1 of IntS11 (green)
and strand β5 of IntS9 (pink) are indicated by the dashed lines in red. The
side chains of the two β-strands are placed next to each other. Interactions
between helix α1 of IntS11 and residues in IntS9 are also shown. Residues
selected for mutagenesis studies are labeled in red. (B) Interactions between
residues in helix α3 of IntS11 (green) and residues in helix α2 of IntS9 (pink).
Residues in strand β1 of IntS11 and strand β5 of IntS9 also contribute to this
part of the interface.
Fig. 3. (A) Molecular surface of the IntS9–IntS11 CTD complex. Residues in
IntS9 that contribute to the interface with IntS11 are colored in pink, and
those in IntS11 that contact IntS9 are in green. The other residues are in
gray. (B) An “open-book” view of the IntS9–IntS11 interface showing the
surface area of IntS11 in contact with IntS9 after 90° rotation around the
vertical axis. (C) An open-book view of the IntS9–IntS11 interface showing
the surface area of IntS9 in contact with IntS11 after 90° rotation around the
vertical axis. (D) Molecular surface of IntS11 colored by sequence conserva-
tion, produced by ConSurf (40). Highly conserved residues are labeled. The
color scheme runs from dark red (highly conserved) to cyan (poorly con-
served) (color bar at bottom). The view is the same as in B. (E) Molecular
surface of IntS9 colored by sequence conservation.
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minimal CTDs of IntS9 or IntS11 and observed a complete loss of
interaction based on the yeast two-hybrid assays (Fig. 4 C and D).
To extend upon these data, we also introduced the point
mutations into the full-length cDNAs encoding IntS9 and
IntS11 and tested their impact on the interaction using a coim-
munoprecipitation assay. We had established previously that the
IntS9–IntS11 heterodimer could withstand rigorous washing with
detergent and high salt (19) and therefore tested these same
conditions here. We transfected various myc-tagged IntS9 cDNAs
with HA-tagged wild-type IntS11 into 293T cells and subjected
the lysates to anti-HA immunoaffinity matrix followed by probing
with anti-myc antibodies using Western blot analysis. Only the
wild-type IntS9 was able to coimmunoprecipitate with IntS11;
none of the mutants was detected in the immunoprecipitate (Fig.
4E). Importantly, all four mutants tested were expressed at levels
similar to the wild type, suggesting that these proteins are folded
properly and that the lack of coimmunoprecipitation is caused by
the disruption of the interaction by the mutations.
We then performed the reciprocal coimmunoprecipitation in
which we transfected HA-tagged wild-type IntS9 with several
mutants of IntS11. We also included a catalytic mutant (E203Q,
mutating one of the conserved residues in the active site of the
metallo-β-lactamase domain) as a control; this mutation is not
expected to disrupt interaction with IntS9. Both the wild type
and the E203Q mutant of IntS11 were able to interact with IntS9,
but the interface mutants did not show interaction (Fig. 4F).
Finally, we extended these analyses to ask whether disruption of
the IntS9–IntS11 interface inhibits the ability of the heterodimer
to be incorporated into the endogenous Integrator complex. Pre-
viously, we established that purification of the intact INT could be
achieved by pulling down a FLAG-tagged IntS11 from nuclear
extracts derived from stable cells lines expressing FLAG-IntS11
(33). Therefore, we created cells stably expressing either wild-type
IntS11 or a mutant IntS11 and purified the INT from nuclear ex-
tracts made from these cells lines. Almost no IntS9 was associated
with the mutant IntS11, as expected, but we also observed a sig-
nificant reduction in the levels of copurifying IntS3, IntS4, and
IntS10 relative to wild-type IntS11 (Fig. 4G). Taken together, these
results strongly validate the structure of the IntS9–IntS11 CTD
complex and demonstrate that this region is essential for the two
Integrator subunits to interact and may play a significant role in the
incorporation of the IntS11 endonuclease into the endogenous INT.
Functional Importance of the IntS9–IntS11 Complex. Currently an
in vitro system is not available to assess INT function. Therefore,
to address the functional relevance of the IntS9–IntS11 inter-
actions observed in the crystal structure, we used a cell-based
fluorescence reporter that assays for UsnRNA 3′-end formation
(34). The U7-GFP reporter consists of the human U7 snRNA
promoter, the U7 snRNA gene body, a 3′ box sequence for
snRNA 3′-end processing, and then the coding sequence for
GFP followed by a strong polyadenylation signal (Fig. 5A). When
transfected into untreated cells, the reporter gives rise to no GFP
expression because of the 3′-end processing activity of endoge-
nous INT. If cells are transfected with siRNA targeting INT
subunits, the efficiency of snRNA 3′-end formation is reduced,
resulting in transcriptional read-through and the production of a
GFP mRNA containing the U7 snRNA as its 5′ UTR using the
native start codon of GFP because U7 lacks an AUG sequence.
We transfected cDNA constructs containing silent point mu-
tations rendering them RNAi-resistant into IntS9- or IntS11-
depleted cells to determine how effective these constructs are at
restoring INT activity through the reduction of GFP expression.
In control siRNA-treated cells, we detected little to no expres-
sion of GFP after transfection with the U7-GFP reporter (Fig. 5
B and C). In contrast, we could detect robust GFP expression in
cells treated with siRNA targeting either IntS11 or IntS9. Ex-
pression of RNAi-resistant myc-tagged wild-type IntS11 or IntS9
could reduce GFP expression nearly back to the levels observed
in control siRNA-transfected cells. We observed that, as expec-
ted, the E203Q catalytic mutant of IntS11 was unable to rescue
U7 snRNA processing (Fig. 5B). Most importantly, mutations in
IntS11 or IntS9 that disrupt the interactions between their CTDs
also failed to rescue U7 snRNA processing, despite being
expressed at levels similar to the wild-type protein (Fig. 5 B and
C). Finally, we created stable cell lines expressing either RNAi-
resistant wild-type IntS11 or a subset of the heterodimerization
IntS11 mutants and assessed the levels of misprocessed, endog-
enously expressed U2 or U4 snRNA after knockdown. Upon
depletion of IntS11 we observed an ∼25-fold increase in the
levels of misprocessed snRNA relative to the levels observed in
control siRNA-treated cells (Fig. 5D). This level of misprocess-
ing was similar to what we observed in Drosophila S2 cells upon
depletion of INT subunits (35). The levels of misprocessed
snRNA present in IntS11 knockdown cells could be rescued upon
stable expression of the wild-type IntS11, but, as in the U7-GFP
reporter experiments, we did not observe any rescue of snRNA
misprocessing in cells expressing RNAi-resistant IntS11 hetero-
dimerization mutants (Fig. 5D). Collectively, these results dem-
onstrate that interactions observed in the structure of the IntS9–
IntS11 CTD complex are as critical to INT activity in snRNA
processing as the residues within the active site of IntS11.
Discussion
Although a role for IntS11 in the cleavage of UsnRNA and
eRNA has been established using mutations of the metal-
coordinating residues within the active site, the molecular
mechanism by which IntS11 is recruited to these substrates and
Fig. 4. Biochemical studies confirm the structural observations on the
IntS9–IntS11 CTD complex. (A) Yeast two-hybrid assay to define the minimal
region of IntS11 sufficient to bind IntS9. (Upper) Ten amino acid deletions
starting from residue 490. (Lower) Ten amino acid deletions starting from
the C terminus of IntS11. AD, activation domain; BD, DNA-binding domain;
VA, vector alone control. (B) Yeast two-hybrid assay to define the minimal
region of IntS9 sufficient to bind IntS11. (C) Yeast two-hybrid assay using the
minimal regions of IntS9 and IntS11 sufficient for their interaction, with
structure-based mutations in IntS11 CTD. (D) Yeast two-hybrid assay using
the minimal regions of IntS9 and IntS11 sufficient for their interaction, with
structure-based mutations in IntS9 CTD. (E) Coimmunoprecipitation of full-
length myc-tagged wild-type and mutant IntS9 with full-length wild-type
HA-tagged IntS11. Proteins bound to HA affinity resin were probed with
anti-myc antibody by Western blot (WB). (F) Coimmunoprecipitation of full-
length myc-tagged wild-type and mutant IntS11 with full-length wild-type
HA-tagged IntS9. (G) Purification of endogenous INT from stable 293T cells
expressing either wild-type FLAG-IntS11 or the heterodimeric mutant
(R510P, T512P) using FLAG affinity resin.









carries out specific endonucleolytic processing is not known. The
structure of the IntS9–IntS11 CTD heterodimer reveals an ex-
tensive molecular interface mediated by numerous interactions
and explains the high binding affinity that has been reported for
the two proteins. The structure also indicates a role for the
catalytically inactive IntS9, which provides a distinct structural
surface established only through heterodimerization with IntS11.
This specific interface could allow recognition of only the active
cleavage factor by the other members of the INT complex. Such
a mechanism also might be operative for CPSF-73 and CPSF-
100 in the pre-mRNA 3′-end processing machinery.
The CTDs of IntS9 and IntS11 are substantially larger than
that of the homologous enzyme RNase J, which is comprised of a
three-stranded β-sheet and two facing α-helices (23). Deletion of
the RNase J CTD makes the enzyme become monomeric in
solution and also abrogates all catalytic activity in vitro, even
though the ΔCTD RNase J retains structurally intact metallo-
β-lactamase and β-CASP domains. Based on results from our
studies using the U7-GFP reporter, it is clear the mutations that
specifically disrupt the formation of the IntS9–IntS11 CTD
heterodimer have effects equivalent to those of the mutation
(E203Q) that disrupts the active site of IntS11. This finding
demonstrates that the binding to IntS9 is essential for IntS11
function in cells and suggests that homo- or heterodimerization
of β-CASP RNA endonucleases either plays an important role in
the recruitment to RNA substrates or somehow impacts the
activity of the catalytic domain. One potential explanation is that
formation of the IntS9–IntS11 CTD complex induces obligatory
conformational changes in IntS11, for example in the interface
between IntS11 metallo-β-lactamase and β-CASP domains, to
allow access to and cleavage of the RNA substrates. This struc-
tural requirement would ensure that any IntS11 not associated
with IntS9 would be inactive, and, by analogy, the same would
hold true for CPSF-73 and CPSF-100.
CTD heterodimerization may provide another important
function in addition to modulating the catalytic activity of IntS11.
In this model, the IntS9–IntS11 CTD complex produces an essential
surface that is recognized by a different member of the Integrator
complex to recruit the dimerized cleavage factor into the complex.
This mechanism would provide an elegant way of ensuring that only
the authentic IntS11–IntS9 heterodimer is incorporated into INT
and could represent an additional layer of regulation to prevent
spurious cleavage events. This model is supported by our experiments
demonstrating that a heterodimer-deficient IntS11 failed to associate
with other members of INT in addition to IntS9 (Fig. 4G). Indeed, a
large scaffolding protein, symplekin, interacts with CPSF-73 and CPSF-
100 and likely plays a critical role in mediating cleavage of pre-mRNA
substrates (13–16). Such a protein is likely to exist within the In-
tegrator complex, but currently there is no candidate based upon
sequence comparison with symplekin.
The linkers between the metallo-β-lactamase domain and the
CTD in IntS9 and IntS11 are expected to contain secondary
structure elements (Figs. S1 and S2) and hence are likely to be
organized structurally. In the structure of RNase J, the linker
also contains secondary structure elements and has interactions
with both domains (23). Exactly how the linkers in IntS9 and
IntS11 connect the two parts of these proteins remains to be
determined. It is possible that this region of the proteins func-
tions to communicate heterodimerization to the active site to
allow cleavage to take place.
Methods
Protein Expression, Purification, and Crystallization. The C-terminal domain of
human IntS11 (residues 491–600) was subcloned into the pET28a vector
(Novagen), which introduced an N-terminal His-tag. The C-terminal domain
of human IntS9 (residues 582–658) was subcloned into pCDFDuet vector
(Novagen) without any affinity tag. The two proteins were coexpressed in
Escherichia coli BL21Star (DE3) cells at 23 °C for 16–20 h. The cells were lysed
by sonication in a buffer containing 20 mM Tris (pH 8.5), 200 mM NaCl, and
5% (vol/vol) glycerol. The IntS9–IntS11 heterodimer was purified by Ni-NTA
(Qiagen) chromatography. The eluted protein was treated overnight with
thrombin at 4 °C to remove the His-tag and was further purified by gel fil-
tration chromatography (Sephacryl S-300; GE Healthcare). The purified
protein was concentrated to 30 mg/mL in a solution containing 20 mM Tris
(pH 8.5), 200 mM NaCl, and 10 mM DTT before being flash-frozen in liquid
nitrogen and stored at −80 °C.
Crystals of the IntS9–IntS11 complex were obtained at 20 °C using the
sitting-drop vapor-diffusion method. The reservoir solution contained 0.1 M
Bis-Tris (pH 6.5) and 21–24% (wt/vol) PEG 3350. The protein concentration
was 10 mg/mL. Crystals took 2 wk to grow to full size. A heavy-atom de-
rivative was prepared by soaking native crystals in the mother liquor with
1 mM HgCl for 3 h. All crystals were cryo-protected by the reservoir solution
supplemented with 5% (vol/vol) ethylene glycol and were flash-frozen in
liquid nitrogen for data collection at 100 K.
Data Collection and Structure Determination. X-ray diffraction data of native
and heavy-atom–derivative crystals were collected at a wavelength of 0.979 Å
on an ADSC Q315R CCD at the 5.0.1 beamline of Advanced Light Source
(ALS). The diffraction images were processed with the HKL program (36).
The crystals belonged to space group P21 with cell dimensions of a = 63.0 Å,
b = 67.8 Å, c = 98.6 Å, and β = 100.6°. There are four copies of the IntS9–
IntS11 complex in the crystallographic asymmetric unit.
A native dataset was collected to 2.1-Å resolution, and the derivative
dataset was collected to 2.3-Å resolution. Four Hg atoms were located and
used for phasing by the AutoSol routine in PHENIX (37), using the single
isomorphous replacement (SIR) method. Most of the protein residues were
Fig. 5. Functional importance of the IntS9–IntS11
interactions for snRNA 3′-end processing. (A) Sche-
matic of the U7-GFP reporter that is transfected into
human cells. (B) Western blot analysis of lysates from
HeLa cells transfected with either control siRNA or
IntS9 siRNA that then were transfected with either
empty vector or myc-tagged RNAi-resistant IntS9. All
cells were also transfected with the U7-GFP reporter.
(C) The same analysis as in B, except that cells were
treated with siRNA targeting IntS11 rather than
IntS9. (D) Quantitative RT-PCR analysis of misprocessed
U2 or U4 snRNA that are endogenously expressed.
The bar graph represents the fold increase in the
levels of misprocessed snRNA; data show the results of
biological triplicates; error bars represent the SD from
the mean.
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automatically built by the AutoBuild routine in PHENIX, and further manual
building was carried out with the program Coot (38). The structure was re-
fined using PHENIX. The crystallographic information is summarized in
Table S1.
Yeast Two-Hybrid Assays. Yeast two-hybrid assays were carried out in PJ69-4a
and PJ49-4alpha. Human IntS11 or IntS9 CTD fragments were cloned into
either pOBD or pOAD vectors using conventional cloning. Clones were se-
quenced to verify identity; PCR primers are available upon request. pOBD
plasmids were transformed into PJ69-4a yeast and were selected on
tryptophan-dropout medium; pOAD plasmids were transformed into PJ49-
4alpha yeast and were selected on leucine-dropout medium. Double trans-
formants were created by mating the yeast strains followed by selection on
medium lacking both tryptophan and leucine. Interactions were tested
through serial dilution of diploid yeast followed by plating on medium
lacking tryptophan and leucine or on medium lacking tryptophan, leucine,
and histidine that also was supplemented with 1 mM 3-amino-1,2,4-triazole.
Coimmunoprecipitation. IntS11 and IntS9 cDNAs were cloned into pcDNA3
expression plasmids and were subjected to site-directed mutagenesis as
described previously (10). All clones were sequenced to confirm identity.
Approximately 5 × 105 293T cells (in one well of a six-well plate) were
transfected with 1 μg of each plasmid encoding either HA-tagged or myc-tagged
IntS9 or IntS11 using Lipofectamine 2000 according to the manufacturer’s in-
structions (Thermo Fisher). Forty-eight hours after transfection, cells were lysed
in 500 μL of denaturing lysis buffer (19), and 50 μL was removed for input
lanes. To the remaining lysate, 20 μL of anti-HA affinity resin (Sigma) was
added and incubated at 4 °C for 1 h with rotation. Following immunopre-
cipitation, beads were washed three times in lysis buffer and eluted with SDS
loading buffer. Western blots were performed using SDS/PAGE as described
previously (19). Affinity purification of FLAG-IntS11 was conducted essentially
as described previously (33). Western blots were conducted using antibodies
raised to IntS3 (PTGlab), IntS4 (Bethyl), IntS9 (Bethyl), IntS10 (PTGlab), and
FLAG epitope (Sigma).
Cell Culture and RNAi Assays. RNAi-rescue experiments were performed using
HeLa cells, which were grown under standard conditions using DMEM and
10% FBS. Cells were plated initially at 8.5 × 104 cells per well in a 24-well
plate. Cells were transfected with control siRNA (GGUCCGGCUCCCCCA-
AAUGdTdT), IntS9 siRNA (GAAAUGCUUUCUUGGACAAdTdT), or IntS11 siRNA
(CAGACUUCCUGGACUGUGUdTdT) using a two-hit protocol (39). Twenty-four
hours after the second siRNA transfection, cells were transfected a third time
with 500 ng of the U7-GFP reporter (19) and with 200 ng of empty pcDNA-myc
vector or with pcDNA-myc where either RNAi-resistant wild-type IntS9/IntS11
or mutant versions were cloned. Two days after the transfection, cells were
lysed in denaturing buffer and probed using Western blot analysis with anti-
bodies raised against GFP (Clontech), IntS11 (Bethyl), or GAPDH (Thermo). To
monitor endogenous snRNA misprocessing, RNA was isolated from cells using
TRIzol (Thermo Scientific) and was subjected to MMLV reverse transcription
according to the manufacturer’s instructions (Life Sciences). Real-time PCR was
conducted using SYBR Green PCR mix on a CFX quantitative PCR machine (Bio-
Rad), and fold calculation was done as described previously (35). Primers to
measure U2snRNA misprocessing are 5′-CTTCGGGGAGAGAACAACC-3′ and
5′-GACACTCAAACACGCGTCA-3′. Primers to measure U4snRNA misprocessing
are 5′-GCATTGGCAATTTTTGACAG-3′ and 5′-GAACCCCGGACATTCAATC-3′.
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